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Foreword  
 
The evaluation of the carcinogenic potential of substances and the methods used differ 
substantially across sectors. Despite differences in testing schemes, the two-year 
bioassay study in rodents represents the standard element.  However, the validity of the 
two-year bioassay has been the subject of considerable debate in the last decade. Issues 
are uncertainty on the relevance to humans; time and resource demand; high animal 
burden and ethical concerns. 
 
In order to provide context for a broad initiative aimed at exploring opportunities to 
improve the whole process of carcinogenicity assessment and to lower its impact on 
animal use and, further the outcome of the Workshop 'Carcinogenicity brain-storming' 
held at the JRC-Ispra in October 2014, The European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL ECVAM) has carried out and analysis of 
carcinogenicity testing across sectors in the European Union. 
 
Results from this analysis are expected to inform initiatives aimed at: a) reducing the 
need for animal use where animal testing is still a requirement; b) ensuring the 
adequate hazard identification and characterization in sectors where animal use is 
banned or limited; and c) where existing methods are not suitable.  
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Abstract  
 
 
The approaches for evaluating the carcinogenic potential of substances, including 
whether carcinogenicity studies should be conducted, differ substantially across sectors. 
Despite variations in testing schemes, the two-year bioassay study in rodents represents 
the standard element across all sectors.   
 
The validity of the two-year bioassay has however been questioned in the last decade. 
Uncertainty is associated with the extrapolation of data from rodents to humans. 
Furthermore, these studies are extremely time and resource-consuming and the high 
animal burden has raised ethical concerns. For all these reasons, there is a strong 
demand for alternative strategies and methods in this area. The development of new in 
vitro methods for carcinogenicity testing, however, has progressed slowly and those 
available are far from being accepted for regulatory decision making, especially when 
evaluating the carcinogenicity of non-genotoxic chemicals or specific classes of 
compounds such as biologicals, microorganisms and nanomaterials. 
 
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL 
ECVAM) has carried out an analysis of carcinogenicity testing requirements and 
assessment approaches across different sectors. This consisted of: a systematic review 
of the different regulatory testing schemes; an analysis of the number of animals used 
per sector; an estimation of the number of carcinogenicity and genotoxicity studies 
conducted or waived in respect of the number of substances authorized per sector per 
year; a review of the type of justifications for waiving the two-year bioassay.  
 
Results from this analysis will provide context for initiatives aimed at: 1) reducing the 
need for animal use where animal testing is still a requirement; 2) ensuring an adequate 
hazard identification and characterization in sectors where animal use is banned or 
limited; and 3) where existing methods are not suitable.  
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1. Introduction 
 
The incidence of cancer has been estimated as being approximately 3,420,000 new 
cases per year in the European Union (EU) (data are from population-based Member 
States Cancer Registries [1]) and approximately 14 million new cases per year 
worldwide  with a projection to 19.3 million by 2025 [2]. These figures have been rising 
constantly over recent decades making cancer one of the major public health issues and 
burden of disease, in terms of social impact, quality of life and economic impact, 
including cost of illness, phase-specific and long-term and indirect costs [2-5].  
Despite the advances in research/innovation and activities aimed at cancer prevention, 
the complexity of the disease together with its multi-faceted causes makes its defeat a 
slow process.  
 
Carcinogenesis, the process of initiating and promoting cancer, is considered to be a 
multi-hit/multi-step process from the transition of normal cells into cancer cells via a 
sequence of complex biological interactions. Cells are no longer fully responsive to 
signals that regulate differentiation, proliferation, survival or death. Changes affecting 
normal cells are the results of interactions between one's genetic features, diet, life-
style, hormonal balance, environment and xenobiotics. Xenobiotic insults include: 
physical stressors such as UV and ionizing radiations; chemicals including natural and 
man-made substances and their derivatives; biological ones such as viruses-, bacteria- 
and parasites-induced infections (e.g. HIV, hepatitis C/B, HPV and H. pylori).  
  
Aging also plays a predominant role in the development of several types of cancer. In 
fact, the incidence of cancer rises dramatically in people aged 50 or older, most likely 
due to a build-up of adverse effects over time. Accumulation of cellular and DNA 
damage, induced by multiple insults is often combined with age-dependent deficiency of 
cellular and DNA repair mechanisms.   
 
Along with the variety of factors involved in cancer development, chemical substances 
induce cancer disease through a variety of mechanisms. Agents can act by directly 
causing alteration to DNA structure (genotoxic) and thereby affecting the integrity of the 
genome or indirectly, affecting its architecture and/or functionality (epigenetic, e.g. 
alternative states of gene expression, complex hyper- or hypo-methylation of DNA, 
histone modifications, inducing changes in protein folding and nucleosomal remodelling, 
RNA interference) or by specific mechanisms that do not involve genotoxicity (non-
genotoxic, e.g. hormonal dysregulation, immune suppression, inflammation, etc.) [6]. 
Hence, a thorough evaluation of the carcinogenic potential of substances, which 
considers all the changes in physiology at cellular and molecular level in animals and 
humans together with relevant data on exposure, represents an important step forward 
to prevention and ultimately to safety of human health.  
Thousands of chemicals are in common use on a daily-basis, but only a portion of them 
have undergone significant toxicological evaluation. Based on the International Agency 
for Research on Cancer (IARC) classification scheme [7], 118 chemicals have been 
classified as 'known human carcinogens' (Group 1), more than a double instead, 369 
(Group 2A-2B) are classified as 'probably or possibly' human carcinogens (from IARC 
website as for 22-02-2016) [7-9]. Yet, many others have not been evaluated for their 
long-term impact on human health.  
An initial screening of substances included in Annex VI of the CLP Regulation [10], which 
ensures that the hazards presented by substances are clearly communicated to workers 
and consumers in the European Union, reported 406 substances classified as CMRs 
(carcinogens/mutagens/toxic to reproduction; Carc. 1A or Carc. 1B, and/or Muta. 1A or 
Muta. 1B, and/or Repr. 1A or Repr. 1B) among the substances registered with ECHA and 
665 matches among those notified (which includes the registered substances) [11]. 
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Carcinogenicity evaluation represents an essential component of the safety assessment 
of all types of substances, relevant to European and International legislation aimed at 
the protection of human health. In fact, cancer risk assessment forms the basis for 
prevention and intervention, along with several initiatives in the area of surveillance and 
social impact where the World Health Organization (WHO) approaches (e.g. The 
STEPwise Approach to Chronic Disease Risk Factor Surveillance; The WHO Global 
InfoBase) complement those of the European Commission. For instance, European 
activities related to breast cancer are aimed to ensuring the implementation of evidence-
based practices throughout the entire breast cancer prevention programs, including 
screening and diagnosis; to implementing population-based cancer registries in order to 
obtain information from all new cases and to provide a basis for research on cancer 
causes and outcome; to ensuring and harmonizing quality of breast cancer services 
across European Countries [12-14].  
Substances are defined as carcinogenic if after inhalation, ingestion, dermal application 
or injection they induce (malignant) tumours, increase their incidence or malignancy, or 
shorten the time of tumour occurrence.  
Carcinogenicity assessment generally requires the conduct of either a carcinogenicity in 
vivo study [OECD TG 451, 15] or a combined chronic toxicity/carcinogenicity test [OECD 
453, 16]. Introduced as a regulatory requirement in the early '60s, the two-year 
bioassay in rodents is widely regarded as the 'Gold standard' and it represents the 
traditional approach of conducting long term study for the evaluation of cancer hazard 
and potency. Its adequacy to predict cancer risk in humans, however, has been the 
subject of considerable debate [17-18].  
In order to provide context for a broad initiative aimed at exploring opportunities to 
improve the whole process of cancer hazard identification and to lower its impact on 
animal use and before embarking on any new activity, a two-level approach has been 
considered critical.  
First, and the main goal of this report, is to review the actual demand of animal-based 
carcinogenicity testing across sectors, based on: different approaches used by each 
sector to satisfy regulatory requirements; the actual number of animals/experiments 
performed for regulatory assessment of carcinogenicity; the number of chemical product 
authorizations released within the EU market. This work will be followed by a 
comprehensive review and analysis of the relevance of, and possible gaps in, the current 
available testing paradigm. 
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2. Material & Methods  
 
For a systematic evaluation of carcinogenicity testing in the EU and its impact on animal 
use, the information available was approached at different levels:  
 
 First level of study aimed at reviewing the regulations and policies currently 
adopted in the European Union and the definition of regulatory requirements for 
carcinogenicity testing across different sectors. 
 
 The number of animal used in the European Union formed the second level of 
investigation. The primary source of information was represented by the DG ENV 
reports then, reports from The Home Office of Statistics were also consulted for 
an overview on the number of experimental procedures as performed in the UK. 
Those reports provided a rough estimation of the number of animal used for 
scientific purposes in Europe in the past decade and specific to toxicological and 
safety purposes and to the trend across sectors.  
 
 A third level of investigation referred to the analysis of authorization dossiers for 
each substance across different sectors, and an in-depth analysis of two different 
years 2011 and 2014. The aim was to sourcing out information relating the 
demand and actual performance of studies of carcinogenicity and genotoxicity to 
satisfy regulatory requirements. This latter study was performed without taking 
into account the number of animals used.  
Additionally, since carcinogenic potential cannot be evaluated without evaluating DNA 
damage, the latter being an essential component of carcinogenesis, it was also decided 
to collect information on in vitro and in vivo genotoxicity studies. 
 
 
2.1 Regulatory requirements for carcinogenicity testing across 
sectors  
Information on current policies related to consumers, environment health and food 
safety legislations can be directly retrieved from the European Commission website [19]. 
This includes Regulations and Directives adopted in regard of the different products, that 
are made available on the EU market and related requirements for regulatory testing, 
including carcinogenicity,  
Information on carcinogenicity testing approaches specific to each sector was obtained 
from the guidance documents (SCCS Notes of guidance, ECHA guidance documents, 
etc.) of different EU Agencies (DG GROW, DG SANTE, EFSA, EMA, ECHA) in charge of the 
evaluation and authorization of products. These documents are in support of the 
legislations and guide the fulfilment of testing requirements.  
Information on testing of carcinogenicity has been also retrieved from those guidelines 
published by International Organizations in charge of harmonization of guidance 
documents. Those are: the International Council on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) and the Trilateral 
(EU-Japan-USA) Programme aimed at harmonising technical requirements for veterinary 
product registration (VICH). For testing procedures, the Organisation for Economic Co-
operation and Development (OECD) Guidelines for the Testing of Chemicals for health 
effects have been consulted (Table 1). The above documents were also consulted in 
relation to waiving opportunities in the different sectors. 
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2.2 Data on number of animals used for scientific purposes  
The European Commission publishes, on a three-year basis, a report on the number of 
animals used for experimental and other scientific purposes across the Member States 
(MS).  
The latest available report, published by the European Directorate General for the 
Environment (DG ENV) is from 2013 [20] and summarizes the number of animals used 
in 2011 by 27 MS (Table 1). Data on purposes of the experiments, percentage and 
actual number of animals per toxicity endpoint and type of product were collected and 
reported.  
The Home Office Statistics in the UK of scientific procedures (intended as number of 
experiments) on living animals are published yearly but they consider procedures 
performed in UK only. Both the European and the UK documents were consulted to 
retrieve information on the number of animals used and experiments performed for 
different purposes and specifically for genotoxicity and carcinogenicity testing 
between2004 and 2014 [21-23]. 
 
 
2.3 Data on carcinogenicity and genotoxicity studies across 
sectors  
The actual number and type of carcinogenicity and genotoxicity studies is scattered 
across different databases; this prompted us to systematically collect data for each 
sector. The sectors considered in this review include: industrial chemicals, biocidal 
products, medicines for human and veterinary use, pesticides, and cosmetics.  
We made use only of information publicly available from the competent authorities 
responsible for evaluating and authorising the marketing of products within Europe 
(Table 1). First, the analysis on the number of authorizations for different sectors was 
performed. Secondly, information on the number and type of studies performed for 
carcinogenicity and genotoxicity endpoint was retrieved from the registration dossiers.  
 
The review of available dossiers did not include the exact number of animals used for the 
relative studies, for this reason data reported from the registration dossiers might not 
completely overlap with those collected from the DG ENV Report [20] on the number of 
animals used for carcinogenicity and genotoxicity testing. 
 
 For industrial chemicals, specific toxicological endpoint information was retrieved 
from the REACH dossiers database stored in the European Chemicals Agency 
(ECHA) dissemination website (Table 1), since its first launch in 2009. In 
addition, the ECHA 2nd report on 'The Use of Alternatives to Testing on Animals 
for the REACH Regulation' [24] was consulted.  
 
 Similarly, information on biocidal products was retrieved from the ECHA 
dissemination website as on March 10, 2015, from the database on biocides.  
 
 Human and veterinary medicines data were retrieved from the European 
Medicines Agency (EMA). The Agency publishes a European Public Assessment 
Report (EPAR) for every human and veterinary medicine for which a central 
marketing authorisation by the European Commission is granted or refused 
following an assessment by the EMA's Committees for Medicinal Products for 
Human Use (CHMP) or for Veterinary Use (CVMP), respectively. EPARs are full 
scientific assessment peer reviewed reports.  
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 The EU pesticide database is hosted on the DG SANTE website. For pesticides, 
detailed information regarding toxicity testing was retrieved, when available, from 
the European Food Safety Authority (EFSA) Draft Assessment Reports (volume 3 
Annex B/6), where studies on carcinogenicity, in vitro and in vivo genotoxicity are 
reported for each substance and published on EFSA website.  
 
 Information on cosmetics was retrieved from the EU Scientific Committee on 
Consumer Products [http://ec.europa.eu/health/scientific_committees/consumer 
_safety/index_en.htm]. When preparing its policy and proposals relating to 
consumer safety, public health and environment, the Commission relies on 
independent Scientific Committees to provide it with sound scientific advice and 
draws its attention to new and emerging problems. The Scientific Committees can 
call on additional expertise from a pool of scientific advisors and a database of 
experts. The Committee provides Opinions on health and safety risks (chemical, 
biological, mechanical and other physical risks) of non-food consumer products 
and services among those, cosmetic products and their ingredients.  
 
It is worth noting that SCCS opinions concern mainly particular classes of 
cosmetics such as hair dyes, preservatives, nanomaterials, UV filters, CMRs, 
border-line products (those is not clear between countries whether a particular 
product is a cosmetic product under cosmetics legislation or it falls under other 
sectorial legislation) which enter specific Annexes of the EC Regulation 1223/2009 
[25]. 
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Data on:  DG - Agency - Organization Publicly available information 
Number of Animals 
used in EU 
European Commission   DG ENV 
http://ec.europa.eu/environment/chemicals/lab_anim
als/home_en.htm  
Statistics in UK Home Office Gov UK 
https://www.gov.uk/government/policies/ensuring-
research-and-testing-using-animals-is-safe-and-
reasonable  
Pesticides 
European Food Safety Authority 
(EFSA) 
http://www.efsa.europa.eu/en/publications.htm 
Human medicines 
European Medicines Agency (EMA) 
 
 & ICH 
http://www.ema.europa.eu/ema/index.jsp?curl=pages
/medicines/landing/epar_search.jsp&mid=WC0b01ac0
58001d124 
 
http://www.ich.org/home.html 
Veterinary medicines 
European Medicines Agency (EMA) 
 
 & VICH 
http://www.ema.europa.eu/ema/index.jsp?curl=pages
/medicines/landing/vet_epar_search.jsp&mid=WC0b0
1ac058001fa1c 
 
http://www.vichsec.org/what-is-vich.html  
Biocides European Chemicals Agency (ECHA)  
http://echa.europa.eu/regulations/biocidal-products-
regulation;  
http://echa.europa.eu/information-on-
chemicals/active-substance-suppliers 
Industrial chemicals - 
REACH 
European Chemicals Agency (ECHA)  
http://echa.europa.eu/search-chemicals; 
http://echa.europa.eu/information-on-
chemicals/testing-proposals/current 
Cosmetics Ingredients 
European Commission DG SANTE - 
Scientific Committee on Consumer 
Safety (SCCS) 
 
European Commission Impact 
Assessment on the animal testing 
provisions in regulation 1223/2009 
on cosmetics 
 
http://ec.europa.eu/health/scientific_committees/con
sumer_safety/opinions/index_en.htm 
 
http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:52013SC0066  
Legislations European Commission   EURLEX http://ec.europa.eu/legislation/index_en.htm  
Test Guidelines on 
Carcinogenicity 
(internationally agreed 
testing methods) 
Organisation for Economic Co-
operation and Development 
(OECD) 
http://www.oecd.org/chemicalsafety/testing/oecdgui
delinesforthetestingofchemicalsandrelateddocuments.
htm  
Number of animals 
foreseen to be used for 
research projects in 
Germany (Zebet/BfR 
database)
1
 
Bundesministerium für Ernährung 
und Landwirtschaft (BMEL) 
https://www.animaltestinfo.de/  
Table 1. Source of information List of agencies, competent authorities and organizations websites consulted for data 
gathering. 
  
                                           
1 Database on foreseen number of procedures (e.g. cancer studies) and animal usage related to 
research projects proposals within the Academia environment, mainly (as on May 29, 2015).  
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2.4 Methodology 
Firstly, a definition of regulation and policies currently in place at EU level for each sector 
were reviewed as well as guidance documents on carcinogenicity testing and available 
test method guidelines internationally agreed (Results, section 3.1).  
Information on the number of animals for scientific purposes used from 1996 to 2011 
was reported as from the DG ENV Reports with specific emphasis on regulatory 
toxicology and safety and on carcinogenicity and mutagenicity testing across sectors 
(Results, section 3.2).  
The number of product authorizations per sector per year was also considered. Data 
from years 1999-2014 were recorded, whenever available (Results, section 3.3).  
Year 2011 and year 2014 were chosen for an in-depth analysis. This was based on the 
most recent data, published in 2013 and referring to the animals used in 2011 (DG ENV 
Report 2013) and on the basis of REACH registered chemicals data, reported by ECHA in 
a recently published report [24], also referring to data of year 2011 and 2014. Where 
possible, we considered all the new Authorizations/Approvals within each sector per year 
between 2004 and 2014. The above approach was chosen in order to harmonize data 
collected so far. The reference time-period for the analysis was linked to the available 
number of animals used for scientific purposes, collected within the seven reports 
published by the European Directorate General for the Environment (DG ENV) (Results, 
sections 3.4-3.8).  
It is important to bear in mind that data reported within each consulted document refer 
to studies performed 2-3 years (long-term studies, especially) ahead of final publication. 
Thus, the impact on animals used for carcinogenicity testing does not take into account 
ongoing studies. 
While reviewing the authorizations/approval reports across the different product sectors, 
we searched for new active ingredients, renewals of existing substances, new 
formulations, and whether the drug/substance was approved for more indications or new 
use. We examined the freely-accessible earliest versions of the review documents, 
whether Scientific Opinions of Scientific Committees or final Public Assessment Reports. 
Information on carcinogenicity studies and in vitro and in vivo genotoxicity studies were 
retrieved per substance, including number of performed and waived studies with their 
related justifications. 
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3. Results  
 
3.1 Mapping carcinogenicity testing requirements across sectors  
The approaches for evaluating the carcinogenic potential of substances differ 
substantially across various sectors: industrial chemicals, biocides, pharmaceuticals, 
pesticides, etc. For each sector, the different regulations set out recommended data-
driven decision pathways to determine whether carcinogenicity studies should be 
conducted; these rules have been laid down on the basis of human health risk of 
exposure, specific concerns, available information gathered by other toxicity tests and on 
the basis of the final use of each compound (Figure 1).  
Despite the availability of a number of testing schemes and guidelines, the two-year 
bioassays in rodents represent the standard option across all sectors for the evaluation 
of cancer hazard (Table 2). However, these studies, the in-life portion of which alone 
lasts 24 months, are extremely time- and resource-consuming (one million 
Euro/chemical, approximately). Moreover, in the last decade their predictive capacity has 
been strongly questioned due to its poor human specificity in identifying human non-
carcinogens and extrapolating data from rodents to humans [26-34]. Knight et al. had 
even questioned the validity of EPA human carcinogenicity classification in cases where it 
was solely based on conventional rodent bioassay [30-32].   
 
Test 
Method 
OECD Test 
guideline 
Species/Number Objective of the Study Duration of the Study 
Carcinogenicity 
Studies 
TG. 451  
(B. 32) 
Rats and mice  
(50-65/sex/group) 
 
Non-rodents (mainly 
dog) 
(4-6/sex/group) 
Observe test animals 
for a major portion of 
their life span for the 
development of 
neoplastic lesions 
during or after 
exposure to various 
doses of a test 
substance 
Normally 24 months for 
rodents. For specific strains 
of mice, duration of 18 
months may be more 
appropriate [15]. 
Combined 
Chronic toxicity/ 
carcinogenicity 
Studies  
TG. 453  
(B.33) 
Rat (10/sex/group) 
chronic phase; and 
(50/sex/group ) 
carcinogenicity phase 
Identify carcinogenic 
and the majority of 
chronic effects and 
determine dose-
response relationships 
following prolonged 
and repeated exposure. 
Normally 12 months for the 
chronic phase, and 24 
months for the 
carcinogenicity phase [16]. 
Chronic Toxicity 
Studies* 
TG. 452  Rodents (20/sex/group) 
and non-rodents 
(4/sex/group) 
Characterize the profile 
of a substance in a 
mammalian species 
following prolonged 
and repeated exposure. 
Normally 12 months but, 6- 
or 9- month-studies are also 
performed [35]. 
Table 2. Internationally agreed testing methods for carcinogenicity. Data were retrieved from the OECD website. The 
above methods are used by industry, governments and laboratories for the regulatory safety testing of chemicals. *The 
chronic toxicity study is not aimed specifically at testing carcinogenicity but, it can be used for early detection of neoplastic 
lesions. 
 
Above all, the high animal burden with an extensive use of rodents per study (approx. 
850 animals) has raised ethical concerns and a strong demand for alternative 
carcinogenicity strategies and methods.  
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In addition, the EU Directive on animal welfare, which includes an explicit reference 
(Article 4) to the 3Rs principles and the use of alternative test methods [36], had an 
important impact on the regulatory requirements for carcinogenicity testing in the EU. 
The majority of legislations and guidance documents related to toxicity testing, hence 
carcinogenicity, have been revised accordingly in the past years (Figure 1), and some 
new opportunities for enhancing the use of alternative test methods have been 
introduced. 
Considering the link between damage to DNA and cancer development, the genotoxic 
hazard of substances is assessed before embarking into any type of carcinogenicity 
studies. Genotoxicity is assessed through a battery of in vitro and in vivo tests (gene 
mutations in bacteria and mammalian cells; chromosomal aberrations, micronuclei 
formation, unscheduled DNA synthesis or DNA damage in mammalian cells and in 
rodents) (Figure 2). The resulting outcome can guide follow-up testing, i.e. of the long 
term carcinogenicity study in rodents or the justification for waiving it [37, EURL ECVAM 
Strategy on genotoxicity testing]. 
 
 
Figure 1. Legislations and guidance documents across sectors in the European Union. The panel summarizes the most 
relevant pieces of legislations and documents guiding animal use and safety testing specific to carcinogenicity of 
substances across different sectors. All documents are publicly available and information can be retrieved through the links 
reported in Table 1. 
 
The requirements for testing of Industrial Chemicals, regulated by REACH [38], are 
based on a tiered approach. Substances manufactured or imported in Europe in 
quantities less than 1 tonne per year are not tested. Those in the range of 1 to 10 
tonnes per year are tested for limited to local toxic effects. Substances which fall 
between 10 and 1000 tonnes per year are tested for more extensive toxicological 
endpoints.  A carcinogenicity study “may be proposed by the Registrant or may be 
required by ECHA” for chemicals at high tonnage level of production (Annex X, ≥ 
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1000t/y) if: the substance has a widespread dispersive use or there is evidence of 
frequent or long-term human exposure; and the substance is classified as mutagens 
category 3 (GHS category 2) or there is evidence from the repeated dose study/ies that 
the substance is able to induce hyperplasia and/or preneoplastic lesions [39, 40]. 
However, REACH also requires that carcinogenic substances at all tonnage levels be 
identified as substances of high concern, taking into account information from all 
available relevant sources (non-human and human non-testing and testing data) [41, 
42], which can inform on hazard identification, underlying modes of action or 
carcinogenic potency [43]. Also, the classification and labelling as listed in Annex VI of 
CLP Regulation [10] is legally binding and can trigger further assessment under REACH 
whether the substance is considered of high concern (Figure 2).  
 
The Biocidal Products legislation [44] requires carcinogenicity testing for all new active 
substances, unless those are classified as mutagens category 1A and 1B (Figure 2). A 
combined carcinogenicity and chronic repeat-dose toxicity study in the rat, possibly 
through the oral route plus a second carcinogenicity study in a second rodent species, 
the mouse, are usually performed. It is necessary to conduct toxicity studies by the oral 
route for evaluation of consumer safety of active substances that may end up in food or 
feed [44]. 
 
New Human Medicines are generally tested for their potential to induce cancer in 
patients when duration of treatment is continuous for at least 6 months or intermittent 
for a chronic or recurrent condition (e.g. depression, anxiety and allergies) or for defined 
specific causes of concern arising from other investigations [45-50] (Figure 2). Some of 
the factors considered raising concerns are: 1) previous demonstration of carcinogenic 
potential in the product class that is considered relevant to humans; 2) structure-activity 
relationship suggesting carcinogenic risk, 3) evidence of neoplastic lesions from repeated 
dose toxicity studies; 4) long-term retention of parent compound or metabolites 
resulting in local tissue reactions or pathophysiological response. 
For new small-molecule therapeutics, traditional new chemical entities, the safety 
assessment of carcinogenicity consists in long term studies (two-year bioassay studies) 
conducted in rats and mice or one long term study in rats plus alternative 6-month 
mouse transgenic models (rasH2, p53, etc.). The latter being increasingly performed in 
recent years.  
 
In certain cases, the two-year bioassay may not be required on the basis of specific 
characteristic of the drug, indication of use, patient population, route of exposure [47-
49; 51, 52].  
 This is the case of unequivocally genotoxic compounds which are presumed to be 
trans-species carcinogens, implying hazard to humans. Though, carcinogenicity 
testing may be necessary when administration to human is chronic. 
 In specific conditions, the intrinsic hazard of a substance is overruled by the 
patient 'status' and/or even disease burden. For medicines developed to treat life-
threatening or severely debilitating diseases, carcinogenicity testing is either not 
done at all or is conducted post-approval in order to speed up the availability of 
the drug. This can be the case of anti-cancer drugs aimed to ameliorate patient's 
conditions with metastatic tumours.  
 Waiving can be applied also for certain classes of compounds applied topically 
when there is no concern of significant systemic exposure. 
 
For new biotechnology-derived pharmaceuticals, biotherapeutics, the two-year bioassay 
is often not scientifically applicable or technically feasible. The class of bio therapeutics 
includes: proteins and peptides, their derivatives and products of which they are 
components. They can be derived from cell cultures or be produced using recombinant 
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DNA technology including production by transgenic plants and animals. Cytokines, 
plasminogen activators, recombinant plasma factors, growth factors, fusion proteins, 
enzymes, receptors, hormones and monoclonal antibodies are some examples. The 
intended uses can be in vivo diagnostics, therapeutic or prophylactic [53]. For the 
biotherapeutics characteristics such as, no direct genotoxicity, no formation of active or 
genotoxic metabolites and their target specificity, the main concern is that these 
substances may increase the incidence or the growth rate of a specific neoplasm or 
group of neoplasms. The assessment of carcinogenicity may be needed depending upon 
duration of clinical dosing, patient population and/or biologic activity of the product. In 
vitro mechanistic studies can be conducted or specific indices analysis (e.g. cell 
proliferation) can be included in repeated dose toxicity studies [53]. 
Carcinogenicity studies are not performed in vaccines according to the Note for Guidance 
on preclinical pharmacological and toxicological testing of vaccines [54] and the 
Guideline on adjuvants in vaccines for human use [55]. The study is not performed in 
categories of drugs for gene therapy, cellular blood components, vitamins, etc. 
Two-year bioassay does not need to be carried out when testing generic or biosimilar 
medicines (for definition see section 3.6.1). The recently updated version of guidance on 
similar biological medicinal products containing biotechnology-derived proteins as active 
substance [56] states in fact that: 'If the biosimilar comparability exercise for the 
physicochemical and biological characteristics and the non-clinical in vitro studies (see 
step 1) are considered satisfactory and no issues are identified as potentially relevant (in 
step 2) which would block direct entrance into humans, an in vivo animal study is usually 
not considered necessary'. Also: '…Studies regarding safety pharmacology, reproduction 
toxicology, and carcinogenicity are not required for non-clinical testing of biosimilars'. 
 
Figure 2. Testing requirements for the assessment of carcinogenicity across sectors. Principal requirements set for 
carcinogenicity testing as reported within regulations or guidelines for the different sectors (for hazard categories for germ 
cell mutagens, Globally Harmonized System GHS Classification was used). 
Carcinogenicity is also a key component of the safety assessment of veterinary 
medicines that are mostly tested for this endpoint as the human counterparts. 
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However, there are major concerns for veterinary products used in animals which 
provide food to human consumers, as drug residues may remain in food of animal origin.  
The VICH Guideline no. 28, [57] states that the decision on the need of a carcinogenicity 
for residues of veterinary drugs in food for humans study should be based on 1) the 
results of genotoxicity tests, 2) structure-activity relationships, and 3) findings in 
systemic toxicity tests that may be relevant to neoplasia in longer term studies and any 
known species-specificity of the mechanism of toxicity. In addition, to ensure safety of 
human consumer, the European Commission in consultation with EMA has published 
guidance on the evaluation of user safety and on the establishment of maximum residue 
limits (MRLs) for drugs in foodstuffs of animal origin, the procedures of which are laid 
down in those Regulations [58, 59], harmonized specifically with the Committee for 
Medicinal Products for Veterinary Use (CVMP) [60].  
 
Carcinogenicity bioassays consisting of a two-year rat study and an 18-month mouse 
study are generally recommended. With appropriate scientific justification, 
carcinogenicity studies may be carried out in one rodent species, preferably the rat 
(Figure 2). A positive response in either test species should be considered indicative of 
carcinogenic potential. 
 
Clearly genotoxic compounds are regarded as to bear carcinogenic potential unless there 
is convincing evidence that this is not the case. Clearly negative results for genotoxicity 
should usually be taken as sufficient evidence of a lack of carcinogenic potential via a 
genotoxic mechanism. Hence, when substances show to be devoid of 
mutagenic/genotoxic potential in a suitable battery of tests, and show no structural 
alerts, carcinogenicity testing can be waived. 
 
Non-genotoxic carcinogens are generally believed to exhibit a threshold dose for 
carcinogenicity and human exposure to residues of veterinary drugs is low, thus non-
genotoxic compounds should not be routinely tested for carcinogenicity. For extremely 
low level of residues, and consequently negligible human exposure, carcinogenicity can 
be avoided for those compounds. Nevertheless, cancer bioassays are required if: 1) the 
compound is known to be animal or human carcinogen, 2) available systemic toxicity 
studies identify potentially preneoplastic lesions or findings indicative of neoplasia, or 3) 
systemic toxicity studies indicate that compound may be associated with effects known 
to be linked with epigenetic mechanisms of carcinogenicity that are relevant to humans 
[57]. 
 
Some opportunities for waiving the carcinogenicity testing are in place for veterinary 
drugs. As for human medicines, generics (Article 13 of Directive 82 [61]), vaccines or 
biotechnology derived pharmaceuticals are usually not tested. New formulations of 
known ingredients used for human medicines are also not tested for carcinogenic 
potential and the information from single active ingredients is accepted. Also, data 
requirements can be reduced when a substance is classified as MUMS (for minor use 
minor species/limited market) [62]. In this case, species other than major food-
producing animals (cattle, sheep, pigs, chickens, salmons) and major companion animal 
species (cats and dogs) are considered as minor. 
 
Based on the rules laid down for the authorization and the making available on the 
market of Pesticides - Plant Protection Products (PPPRs) [63-65], carcinogenicity 
study is required for all new active substances (Figure 2). Only 'If in exceptional 
circumstances it is claimed that such testing is unnecessary, that claim shall be fully 
justified'. A long-term oral toxicity study and a long-term carcinogenicity study (two 
years) of the active substance shall be conducted using rat as test species; where 
possible these studies shall be combined. A second carcinogenicity study (78 weeks) of 
the active substance shall be conducted using mouse as test species, unless it can be 
scientifically justified that this is not necessary. In such cases, scientifically validated 
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alternative models may be used instead of a second carcinogenicity study. Studies can 
be preceded by range-finding studies in both species and always by a comprehensive 
battery of in vitro and in vivo genotoxicity tests.  
As of March 2013, in vivo testing is no longer permitted for Cosmetic Ingredients and 
Products [25, 66] (Figure 2). The Cosmetics Regulation [25] prohibits the placing on 
the market of cosmetic products containing ingredients, which have been tested on 
animals to meet the requirements for toxicity testing. Some chemical ingredients may, 
however, also need to be registered under REACH [67]. The relationship between the 
marketing ban and the REACH information requirements is as follows: A) Registrants of 
substances that are exclusively used in cosmetics may not perform animal testing to 
meet the information requirements of the REACH human health endpoints, with the 
exception of tests that are conducted to assess the risks to workers exposed to the 
substance. 'Workers' in this context, refers to those involved in the production or 
handling of chemicals on an industrial site, not to professional users using cosmetic 
products as part of their business (e.g. hairdressers); B) Registrants of substances that 
are used for a number of purposes, and not solely in cosmetics, are permitted to perform 
animal testing, as a last resort, for all human health endpoints, C) Registrants are 
permitted to perform animal testing, as a last resort, for all environmental endpoints.  
The decision on the carcinogenic potential of mutagenic or genotoxic substances may be 
made on the outcome of in vitro mutagenicity tests. A positive in vitro result in 
mutagenicity testing is seen as indicative for the carcinogenic potential of substances. In 
vitro mutagenicity tests are quite well developed, although they suffer from a low 
specificity. Due to the relation between mutations and cancer, these genotoxicity tests 
can be seen as a pre-screening for carcinogenicity. A positive result in one of the 
genotoxicity tests may be indicative for considering a substance as putatively 
carcinogenic. Usually these substances are not further pursued in development.  
At present, generally accepted alternative in vitro methods for carcinogenicity with OECD 
Test Guidelines are not available. There are promising in vitro approaches which may be 
helpful to recognise genotoxic as well as non-genotoxic carcinogenic substances. For 
instance, the Cell Transformation Assay (CTA) may provide additional information when 
used as a follow-up assay for confirmation of in vitro positive results from genotoxicity 
assays, typically as part of a weight of evidence assessment. It has been demonstrated 
that the CTA has the ability to also detect some non-genotoxic carcinogens; however the 
exact performance in this regard is still under evaluation.  
Research is on-going with regard to in vitro toxicogenomic-based tests for the detection 
of mutagens, genotoxic carcinogens, and particularly non-genotoxic carcinogens. Global 
gene expression profiling via microarray technology and gene patterns covering diverse 
mechanisms of substance-induced genotoxicity can be extracted. These gene 
patterns/biomarkers can be further used as a follow-up of positive findings of the 
standard in vitro mutagenicity/genotoxicity testing battery. In addition to in vitro 
mutagenicity/genotoxicity tests, data from in vitro tests combined with toxicogenomics 
may also be considered in a weight of evidence approach [66]. 
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3.2 Animals used for experimental and scientific purposes in the 
EU  
 
Since 1986, the EU has had in place specific legislation covering the use of animals for 
scientific purposes [68, 69]. On 22 September 2010 the EU adopted Directive 
2010/63/EU [68], which updated and replaced the 1986 Directive 86/609/EEC on the 
protection of animals used for scientific purposes. The aim of the new Directive is to 
strengthen legislation, and improve the welfare of those animals still needed to be used, 
as well as to firmly anchor the principle of the 3Rs2, to Replace, Reduce and Refine the 
use of animals in the legislation. Directive 2010/63/EU took full effect on 1 January 2013 
and it now represents an integral part of the hazard identification and risk assessment 
process. 
The Directorate General for the Environment (DG ENV) has been reporting on a three-
year basis statistics in regard of the actual number of animals used in Europe in different 
sectors and for different purposes. Data have been collected by each Member State (MS) 
since 1996. The 7
th
 report relating to year 2011 is the most recently available at EU 
level [20]. Since the adoption of Directive 2010/63/EU the statistical reporting 
requirements have been fully revised. MSs are currently busy in implementing the new 
data collection rules in the national reports covering year 2014, which they are required 
to make publicly available as per the Directive [68]. EU statistics on animal use report is 
foreseen not before November 2019. 
 
Figure 3 Animals used in Europe.  (A) Total number of animals used for scientific purposes in Europe from 1996 to 2011, as 
reported in DG ENV Reports. Data are not normalized for the number of MSs participating to the survey. (B) Statistics in UK 
showing yearly-basis data on the number of scientific procedures involving animals performed in UK in the last decade, 
2004-2014.  
The DG ENV reports provide an estimate of the number of animals used within different 
sectors and in different scientific areas, in Europe (Figure 3). Over the years the 
methodology applied for data collection and the surveys sent to each MS underwent 
constant modifications and some categories overlapped with each other (i.e. test type or 
specific purposes); also participants to the surveys changed over the years (the number 
of MS increased up to 27). Nevertheless, the number of animals used for scientific 
purposes showed an increase up to year 2005, reaching approximately 12 million per 
                                           
2 Replacement: substitution of insentient material for conscious living higher animals. Reduction: 
reduction in the number of animals used to obtain information of a given amount and precision. 
Refinement: any decrease in the incidence or severity of in humane procedures applied to those 
animals, which still have to be used. 
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year, a slow decrease instead to 11 million is observed between 2005 and 2011 (Figure 
3A).   
Areas of animal use can vary significantly. Animals are employed for basic research, for 
pharmaceuticals research and development, for production and quality control of human 
and veterinary medicines and medical devices, for toxicological and safety assessment, 
for diagnosis of diseases, education and training (Figure 4A).  
It is worth noting that 50% of animals used in Europe (Figure 4A) are employed for 
biological studies/basic research; this signifies almost 6 million animals, mostly rodents. 
Thirty per cent approximately of all animals are used for toxicology testing, safety 
pharmacology and production and quality control of medicines (vaccines, antibodies, 
etc.).  
Roughly 9% of animals are used instead, specifically to satisfy regulatory requirements 
for toxicity and safety evaluation, this percentage corresponds to 1 million animals 
approximately (Figure 4A). Regulatory toxicology, which considers all toxicity endpoints 
(acute, chronic, irritation and skin sensitization, reproductive and developmental, 
ecotoxicity, mutagenicity and carcinogenicity) across all sectors, has shown a steady-
state trend in the number of animals used in years 1999-2011 (Figure 4B).  
 
 
Figure 4 Animals used for experimental and scientific purposes. A) Number of animals used, as percent, on the basis of 
the different scientific purposes. In 2011, over 1 million animals were used for regulatory toxicology and other safety 
evaluation, representing 9% approximately of the total number of animals used in the EU. B) Trend of animals used for 
toxicology and safety evaluation in Europe, between 1996 and 2011. C) Percent number of animals used for toxicity testing 
of selected endpoints. Data were retrieved from the 7
th
 DG ENV Report on animals used for experimental and scientific 
purposes in the EU as in 2011 [20]. 
 
In 2011, year of most recent data gathering, acute toxicity and reproduction and 
developmental studies employed the majority of animals, mainly rodents (ca. 50%, 
Figure 4C). Sub-chronic and chronic toxicity studies involved a substantial number of 
animals, as well (ca. 8%), then irritation and skin sensitization (ca. 4%) (Figure 4C).  
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The analysis of carcinogenicity testing and its impact on the use of animals cannot be 
performed without considering genotoxicity studies that represent the starting point for 
safety evaluation of carcinogenic potential. Thus, as mentioned previously, the impact of 
studies used for both endpoints were analysed throughout the report.  
When compared with the above endpoints, a lower percent of animals has shown to be 
used for carcinogenicity testing. In 2011, 1% (12000 animals approx.) of the total 
number of animals has been employed to conduct cancer studies and 2% (21200 
animals approx.) to conduct in vivo genotoxicity tests.  
 
The number of animals employed for carcinogenicity and genotoxicity studies varied 
largely between 1999 and 2011, as reported by DG ENV (Figure 5A). An overall negative 
trend in terms of animal burden within both areas was observed (Figure 5A).  
However, data from older DG ENV reports (from the first to the third report) need to be 
considered cautiously; as mentioned above, the methodology used for data collection 
changed over the years and the number of MS participating the collection exercise 
changed as well. The decreased impact on animals seems to align with that observed on 
the total number of experimental procedures carried out in the UK during the last decade 
(Figure 5B, analysis performed by UK Statistics Gov.). 
Figure 5. Animals used for carcinogenicity and mutagenicity in Europe. (A) Number of animals used for carcinogenicity 
and mutagenicity regulatory testing in Europe from 1996 to 2011, as reported in DG ENV Reports. Data are not normalized 
for the number of MSs participating to the survey. (B) Statistics in UK showing yearly-basis data on the number of scientific 
procedures involving animals for carcinogenicity and mutagenicity testing performed in UK in the last decade, 2004-2014. 
 
Interestingly, while carcinogenicity and genotoxicity testing seem to exert a minimal 
impact on animal numbers when compared with other endpoints (Figure 4C), the animal 
burden varies significantly when considering different product-types, reflecting the 
differences lying within the rules guiding safety assessment across sectors (Figure 6).  
In fact, the highest number of animals used for the safety assessment of the 
carcinogenic potential has been mainly ascribed to the testing of pesticides, biocides 
human and veterinary medicines for which, regulatory requirements are more 
conservative (Figure 6). In contrast, the full ban on in vivo testing for the safety 
assessment of cosmetics [25, 66] has zeroed the impact of the cancer study in terms of 
animals used for this sector, though in practice cancer studies have not been performed 
since 1999. Similarly, the introduction of REACH Regulation [38] within the industrial 
chemical sector has reduced substantially the requirement for carcinogenicity studies 
(Figure 6), limiting the conduct of two-year cancer studies to high tonnage band 
chemicals, previous submitter testing-proposal and approval by ECHA. 
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The overall number of animals and experimental procedures for in vivo genotoxicity has 
also lowered in the past decade (Figure 5A-B) though, with relevant differences 
depending on type of product (Figure 6).  
 
 
Figure 6. Number of animals used for carcinogenicity and mutagenicity testing. Number of animals used for 
carcinogenicity and mutagenicity testing across different product-sectors. Data were retrieved from the 7
th
 DG 
ENV Report on animals used for experimental and scientific purposes in the EU as in 2011 [20] 
 
Of worth, as shown from data of 2011 (Figure 6), are the striking differences in the 
number of animals used for carcinogenicity versus genotoxicity testing within 
pharmaceutical and agrochemical sectors.  
In the case of human and veterinary medicines, the number of animals used for the 
genotoxicity endpoint doubles that for carcinogenicity. Reasons for the observed 
discrepancy can be several: a) data collected in the DG ENV report are from EU studies 
only, drug development is global (but this is valid for other sectors as well) thus, many 
in vivo studies, two-year bioassay especially, are performed outside Europe also for 
those products entering the European market; b) carcinogenicity studies are often 
conducted late in development, i.e. for those products with strong likelihood to get the 
marketing authorization whereas, genotoxicity studies are conducted at earlier stages of 
development on all products the majority of which will never get a marketing 
authorization and will die during development; c) there is no obvious temporal 
correlation between marketing authorization, conduct of genotoxicity studies and 
conduct of carcinogenicity studies per year, as in the case of DG ENV statistics report. 
Differently, in the case of agrochemicals (Figure 6), a higher number of animals are used 
for carcinogenicity studies compared to those used for genotoxicity. As expected these 
data are in line with the substantial difference between number of animal per study per 
endpoint (50-60 per genotoxicity study; >600 per two-year bioassay). In addition, 
requirements for agrochemicals are extremely conservative and it is supposed that 
carcinogenicity studies are always performed, in two different species and are rarely 
waived. 
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3.3 Product authorizations in Europe  
 
A third level of study related to the EU product marketing authorization dossiers in the 
decade 2004-2014. These, were investigated in order to sourcing out information on the 
actual demand of carcinogenicity and genotoxicity studies per year per sector in the EU. 
Compounds from different product sectors were first grouped by date of authorization in 
the EU market (Figure 7).  
Grouping of pesticides, human and veterinary medicines, and biocides was feasible, 
because of available databases. Data were available since 2004 on a year-base; while a 
systematic data collection for biocides begun in 2009 only. Overall, a constant amount of 
substances have been authorized per year per sector over time, except for human 
medicines, for which a steady-state increase is observed between 2004 and 2014.  
Major variations in the amount of authorized products observed in years 2007, 2009 and 
2011 correlate well with key modifications in regulatory testing requirements: 
introduction of REACH Regulation in 2006, CLP Regulation in 2008, PPPs Regulation in 
2009 [10, 38, 63]. In this context, it is plausible that the extremely high number of 
authorizations of pesticides (approx. 160) in 2009 could be partly due to those newly-
adopted regulatory requirements. Interestingly, out of those 160 authorizations for 
pesticides only one was for a new active ingredient, the remaining were re-submissions 
of pre-existing substances (Figure 7A).  
 
Figure 7. Number of authorizations in the EU between 2004 and 2014.  (A) Data for pesticides, biocides and 
pharmaceutical products. Numbers were calculated on the basis of publicly available information gathered from the 
different databases (EFSA, EMA and ECHA) of authorized active subtances. *Number of new active substances. (B) Number 
of Registration dossiers and unique chemicals as reported for the different REACH deadlines: November 30 2010, May 31
st
, 
2013 and most recent available update, August 21
st
 2015 (ECHA website).  
 
Information for industrial chemicals instead, has been based for the time-being on the 
two available registration deadlines of 2010 and 2013 (Figure 7B), related to high 
tonnage level chemicals only (≥ 100 tonnes/yr and  ≥1000 tonnes/yr).  
 
It is worth noting that the registration applies to substances on their own, substances in 
mixtures and certain cases of substances in articles though, the analytical and spectral 
information provided shall be consistent and sufficient to confirm each substance 
identity. 
 
Based on the above data, the average number of new products on the market per year 
in Europe could be estimated as follows: a) human medicines: 56 authorizations per 
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year, 35 of which being new entities; b) veterinary medicines: 11 authorizations per 
year, 10 of which being new entities; c) pesticides: 38 authorizations per year, 10 of 
which being new active substances; d) biocides: 12 authorizations per year, 5 of which 
being new active substances; e) cosmetic ingredients: 10 approximately; f) Industrial 
chemicals: n.d.. Pharmaceutical sector predominates the market.   
 
This prompted to an in-depth analysis of the marketing authorization dossiers per each 
sector, as presented in the following results section for which year 2011 and year 2014 
were chosen.  
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3.4 Industrial chemicals (ECHA, REACH Dossiers database)  
 
The Regulation has set the following registration deadlines for phase-in3 substances: 
November 30, 2010: for substances manufactured or imported at 1000 tonnes or more a 
year, substances that are carcinogenic, mutagenic or toxic to reproduction above 1 
tonne a year and substances dangerous to aquatic organisms or the environment above 
100 tonnes a year; May 31, 2013: for substances manufactured or imported at 100-
1000 tonnes a year; May 31, 2018: for substances manufactured or imported at 1-100 
tonnes a year.  
Potential manufacturers and importers of the new substances, non-phase-in4, have to 
submit an inquiry to ECHA and subsequently register the substances before they can 
manufacture or import them.  
For the aim of the current analysis we have referred to the report published by ECHA in 
2014 'The Use of Alternatives to Testing on Animals for the REACH Regulation' [24] 
where, a thorough investigation of the dossiers submitted by registrants for the 2010 
and 2013 deadlines (with a cut-off for collecting data set at October 1st, 2013) has been 
performed by ECHA experts. Figure 8 shows the number of endpoint study records (ESR) 
relative to carcinogenicity which represent the number of study summaries provided in 
the ECHA website (as IUCLID format) at the moment of the analysis.  
 
 
Figure 8.1 Carcinogenicity study records under REACH. Number of carcinogenicity study records submitted by registrants 
in the IUCLID database for non-phase-in (A) and phase-in substances (B) of dossiers subjected to analysis in 2011 and 2014. 
Study records for all substances between 100-1000 tonnes/y (Annex IX) and substances ≥1000 tonnes/y (Annex X) relative 
to deadlines 2010 and 2013 were analysed, including phase-in and non-phase-in as reported in [24]. 
 
                                           
3  Substances that fulfil at least one of the following criteria may be considered as phase-in 
substances in accordance with REACH:  1) Substances listed in the European Inventory of Existing 
Commercial Chemical Substances (EINECS); 2) Substances that have been manufactured in the 
EU (including the countries that joined on 1 January 2007) but have not been placed on the EU 
market after 1 June 1992; 3) Substances that qualify as "no-longer polymer''. 
4 All substances that do not fulfil any of the criteria for phase-in substances are considered as non-
phase-in substances. Normally, non-phase-in substances have not been manufactured, placed on 
the market or used in the EU before 1 June 2008, [unless they were notified under the Dangerous 
Substances Directive 67/548/EEC (70; replaced by CLP Regulation)]. 
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Though highly represented for phase-in substances (Fig. 8.1B, Annex X especially), the 
majority of data on carcinogenicity studies were retrieved from published data, IARC 
reports or textbooks. On the other hand, the phase-in substances testing proposals for 
new carcinogenicity studies were reported to be 11 (Fig 8.1B), referring to 6 unique 
experimental studies (UES) and zero for non-phase-in substances (Fig. 8A).  
Since the first deadline in 2010, carcinogenicity studies have been performed for two 
lead registration dossiers, referring to substances: 2-ethoxy-2-methyl propane EC 211-
309-7 (CAS no. 637-92-3) and asphalt oxidized EC 265-196-4 (CAS no. 64742-93-2) 
(ECHA info, as of July 2015).  
Standard requirements for high tonnage level have been mainly fulfilled with read-across 
information, weight of evidence approaches and partly with QSAR data (Fig. 8.1-8.2). 
As expected, experimental studies to assess genotoxicity were more numerous than 
those performed in order to assess the carcinogenic potential of substances.  
 
Figure 8.2 Genotoxicity study records under REACH. Number of study records submitted by registrants in the IUCLID 
database for non-phase-in and phase-in substances of dossiers subjected to analysis in 2011 and 2014. (C and D) Endpoint 
study records 'ESRs' for in vitro genotoxicity information. (E and F) ESRs for in vivo genotoxicity information. Study records 
for all substances between 100-1000 tonnes/y (Annex IX) and substances ≥1000 tonnes/y (Annex X) relative to deadlines 
2010 and 2013 were analysed, including phase-in and non-phase-in as reported in [24].  
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3.5 Biocides (ECHA) 
 
For almost 4420 biocidal products currently on the European market (those with 
released data, Article 95 List, published on February 27, 2015), 656 are unique active 
substances. Of those, 113 substances have been approved in accordance with Directive 
98/8/EC (The Biocidal Products Directive concerning the placing of biocidal products on 
the market, 1998) [71] and EU Regulation 528/2012 [44]; while 521 are currently under 
review and 22 were not approved. 
 
 
Figure 9. Information on biocides. A) Represented product types, as percent of total, within the authorized biocidal active 
substances list, available on ECHA website. B) Number of approved biocidal active substances per year between 2009 and 
2014; data are available since 2009. C) Percent number of authorized biocidal active substances that has undergone 
carcinogenicity, in vitro and in vivo genotoxicity assessment in 2011 (n=17) and 2014 (n=12). 
On average, 12 active substances approximately are authorized per year on the 
European market, the majority being represented by wood preservatives, insecticides, 
rodenticides and repellents and attractants (Fig. 9A-B). Not all of the authorizations 
though regard new active ingredients, as several substances were also assessed under 
PPPs or REACH legislations with respect of the specific human or environmental risk 
and/or the proposed use.  
 
As other types of products, the genotoxic potential is assessed firstly on the majority of 
substances. In the two years considered, 2011 (total authorizations = 17) and 2014 
(total authorizations = 12), genotoxicity tests in vitro were conducted in approximately 
53% (8 out 17) and 42% (5 out of 12) of substances, respectively (Fig. 9C).  
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In vivo genotoxicity studies were integral part of 44% and 33% of assessment reports of 
substances authorized in 2011 and 2014, respectively. For those substances where 
opportunities for waiving genotoxicity in vitro and in vivo experiments were scientifically 
justifiable, supporting data from literature, IUCLID database or read-across were 
presented. In certain cases, based on the nature of the compound, the in vivo studies 
were not feasible (e.g. the compound is similar to warfarin: highly toxic and causing 
primary loss of blood coagulation). 
  
Carcinogenicity studies were conducted in the 31% (5) and 33% (4) of substances in 
2011 and 2014, respectively (Fig. 9C).   
 
It is worth noting that in 2011 only 3 (out of 5) active substances underwent a thorough 
evaluation of carcinogenic hazard, as reported in the respective assessment reports. Two 
out of three compounds were tested by a combined chronic/carcinogenicity study in rats 
plus a second study in mice (chronic or two-year bioassay). A third compound was 
tested by a combined study in rats (TG 453; 16) and one study in dogs 
chronic/carcinogenicity (TG 452; 35) plus one 2yr-mouse study in B6CF and one two-
year study in NMR1 mice (TG 451; 15). Two compounds (out of 5) were instead tested 
in two-year bioassay rats only (TG 451; 15).  
 
In 2014, the two-year bioassay was performed in rats and in mice, for the safety 
assessment of two compounds. In a third case, the two-year bioassay was waived due to 
the non-genotoxic potential of the chemical assessed by a short-term (90-day) study in 
rats only. On a fourth compound, carcinogenicity was tested with a two-year bioassay in 
rats only. Justifications for waiving the carcinogenicity study required in the second 
species were mainly linked to the lack of genotoxic potential or the specificity to the 
animal response.   
 
In one case, the waiving concept was refined also to avoid completely the carcinogenicity 
assessment on the basis of exposure pattern and toxicological profile. Hence, a 
negligible secondary human exposure, very low primary exposure, anticipated lack of 
substance-related non-genotoxic and genotoxic MOA and absence of structural alert 
were the main justifications.  
 
In accordance with requirements set out in the Annex II of the Regulation [44], read-
across data with respect of known chemicals and literature report documents were also 
used to waive carcinogenicity testing.  
 
Detailed information from publicly available dossiers from ECHA website on biocides 
consulted for the analysis is reported in Annex I of this report. 
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3.6 Medicinal products for human and veterinary use (EMA) 
 
3.6.1 Human medicines 
Those medicines for human use authorized within the European market from 2004 to 
2014 through the centralized procedure by the competent authority, the European 
Medicines Agency (EMA), for which there were publicly available assessment histories 
(EPARs), have been searched (Figure 10). This means that many other products, 
authorized through a decentralized procedure yet, without a traceable assessment profile 
history, were not considered for the analysis. 
For a thorough analysis of carcinogenicity studies performed on human medicines, it was 
necessary to consider the type of submission and differences among pharmaceutical 
product classes. In fact, requirements specific to non-clinical as well as clinical aspects 
differ substantially on the basis of: A) the nature of the product (varying form a new 
active pharmaceutical ingredient (API), to a generic substance, a biosimilar, or orphan 
drug5, B) the chemical identity, C) its formulation or D) the final therapeutic use.  
 
Table 3.  Number (as average) and type of submissions at EMA for human medicines between years 2004-2014, as from 
EMA data.* new entities = new chemical entities. These include also vaccines or biotechnology-derived medicines. 
                                           
5 Generic designation A generic medicine is a medicine that is developed to be the same as a 
medicine that has already been authorised, called the 'reference medicine'. A generic medicine 
contains the same active substances as the reference medicine, and it is used at the same doses 
to treat the same diseases. However, a generic medicine's inactive ingredients, name, appearance 
and packaging can be different from the reference medicines. Generic medicines are manufactured 
according to the same quality standards as all other medicines. A company can only develop a 
generic medicine for marketing once the period of exclusivity on the reference medicine has 
expired. This is usually 10 years from the date of first authorisation. 
Biosimilar designation A biosimilar is a biological medicinal product that contains a version of 
the active substance of an already authorised original biological medicinal product (reference 
medicinal product) in the European Economic Area (EEA). Similarity to the reference medicinal 
product in terms of quality characteristics, biological activity, safety and efficacy based on a 
comprehensive comparability exercise needs to be established [54]. 
Orphan designation  To qualify for orphan designation, a medicine must meet a number of 
criteria: 1) it must be intended for the treatment, prevention or diagnosis of a disease that is life-
threatening or chronically debilitating; 2) the prevalence of the condition in the EU must not be 
more than 5 in 10,000 or it must be unlikely that marketing of the medicine would generate 
sufficient returns to justify the investment needed for its development; 3) no satisfactory method 
of diagnosis, prevention or treatment of the condition concerned can be authorised, or, if such a 
method exists, the medicine must be of significant benefit to those affected by the condition. 
Applications for orphan designation are examined by the EMA's Committee for Orphan Medicinal 
Products (COMP), using the network of experts that the Committee has built up. The evaluation 
process takes a maximum of 90 days from validation. 
Type of submissions/year Average (2004-2014) [%] of total 
submissions 65  
authorizations 56 86% 
withdrawn 6 10% 
refused 3 4% 
   
generic drugs 12 18% 
biosimilars 2 3% 
orphan drugs 7 11% 
new entities* 35 55% 
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The expectation that all medicines be tested in two-year rodent studies has been 
undergoing considerable discussion in the past decade. This is not only due to the limited 
human relevance of data, but also to the emerging field of biopharmaceuticals, to a 
more realistic benefit-risk analyses and to the availability of alternative test models. In 
addition, short-term repeat-dose toxicity studies, as well as other in vitro and in vivo 
mechanistic studies are currently used to better understand the human relevance of 
findings in rodents (e.g. toxicokinetic or species-specific effects) or the mechanism and 
associated dose-response for a chemical [72, 73]. Nevertheless, with some exceptions, 
two-year rodent carcinogenicity studies are still conducted for most of small molecule 
pharmaceuticals (SMs). Since genotoxic agents are generally screened out at the 
development phase, two-year carcinogenicity studies are primarily used to assess 
potential non-genotoxic carcinogenicity.  
 
Approximately 50 to 70 assessment reports (EPARs) are published per year (Table 3). 
Based on data retrieved (as on March 20, 2015), roughly 86% of all submitted 
substances are positively evaluated and authorized to enter the European market every 
year; on average, 10% of drugs are withdrawn and 4% per year of all drugs are 
rejected. 
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Figure 10. Information on human medicines. A) Total number of submissions and type of substances per year between 
2004 and 2014. B) Percent number of authorized new substances (excluding generics, biotechnology-derived medicines 
and biosimilars) that has undergone carcinogenicity, in vitro and in vivo genotoxicity testing in 2011 (n=43) and 2014 
(n=45), as from EPARs documents. 
 
In Figure 10A, the 'new entities' portion of medicines showed a steady state increase 
over the years. New entities include both new small molecules and new biotechnology-
derived medicines, the latter being gradually increasing.  
 
Generic and biosimilar drugs introduced into the market between years 2006-2013, 
increased significantly instead, representing almost half of the whole market between 
years 2009 and 2012. The authorization of orphan drugs has increased, as well (Figure 
10A). 34% of authorized products in 2011, for instance, had the 'generic' designation, 
10% in 2014. None of them are normally tested either for carcinogenic potential or in 
vivo genotoxicity. Thus, they do not represent an animal welfare concern. In these 
cases, assessment reports justify the carcinogenicity testing waiving on the basis of 
general principles described in the Summary of Product Characteristics (SmPC) 
information [74, 75]. The non-clinical aspects of the SmPC are considered in line with 
the SmPC of each reference product, already tested. In addition, many generics products 
are also entering the market through a decentralized procedure of authorization, always 
without the need of carcinogenicity testing (two-year bioassay).  
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For this reason, when analysing the percentage of substances undergoing carcinogenicity 
or genotoxicity testing from years 2011 and 2014, as reported in Figure 10B, generics, 
biotechnology-derived medicines and biosimilars were not considered. 
 
As shown in Figure 10B, when taking into account the dossiers submitted for 
authorization in the two years 2011 and 2014, approximately 47% and 42% of all new 
medicines have been tested for carcinogenicity by means of the two-year bioassay, 
respectively. The in vitro genotoxicity tests have been performed for approximately 65% 
and 58% of substances, in 2011 and 2014, respectively. In vivo genotoxicity tests have 
been performed in 58% and 53% of cases, respectively (Figure 10B).  
 
Different types of justifications for waiving the carcinogenicity testing were reported in 
the dossiers, as in the case of medicines for very short-term treatments; life-threatening 
treatments; in the case of extremely short patient's life expectancy.  
A new carcinogenicity testing was not required when information was already submitted 
and evaluated by other authorities (FDA or Japan). New products, as new combinations 
of known substances, could not be tested as well. In other cases information on 
carcinogenic potential could be also obtained from studies conducted post-authorization 
(summarized in Table 6). 
 
Despite the number of alternative approaches to animal testing that are being explored, 
the percent of active substances undergoing carcinogenicity testing to comply with 
current regulatory requirements did not decrease accordingly in recent years. Detailed 
information from publicly available EPARs consulted for the analysis is reported in Annex 
II of this report. 
 
3.6.2 Veterinary medicines 
 
Differently from human medicines, a fewer number of dossiers are submitted to EMA and 
assessment reports (EPARs) published per year. Between 2004 and 2014, the average 
number of submissions in Europe has been approximately 12 per year: almost all the 
submitted dossiers resulted in approvals (90%), 10% instead were withdrawn. Among 
the authorized products, generic drugs account for 11% of total, but none has been 
authorized as biosimilar drug (Table 4 and Figure 11A).  
 
As in the case of human medicines, for the purpose of this analysis, generic and 
biosimilar (none in the case of veterinary products within the period analysed) and 
biotechnology-derived medicines were not considered, since no requirement for 
carcinogenicity testing is generally in place. 
 
 
Type of submissions/year Average (2004-2014) [%] of total 
submissions 12  
authorizations 11 89.6% 
withdrawn 1 9.5% 
refused 0 0.8% 
   
generic drugs      (of those authorized) 1.3 11.3% 
biosimilar drugs (of those authorized) 0 0% 
new entities   (of those authorized) 10 88.7% 
Table 4 Number (as average) and type of submissions at EMA for veterinary medicines between years 2004-2014, as from 
EMA data. 
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As shown in Figure 11B, when taking into account the new substances authorized in 
2011 and 2014, a lower impact on animal use for the testing of veterinary medicines 
compared to the human counterparts is evident.  
 
In total, 24% approximately of 21 authorized substances in 2011 have been tested for 
carcinogenicity. Several were substances well characterized or known to be devoid of 
any genotoxic effect resulting in no carcinogenic potential risk. Instead, none of the 18 
substances authorized in 2014 have been tested for carcinogenicity on the basis of 
different justifications.  
 
Specifically, in 2014, 12 out 18 substances were vaccines, thus requiring nor 
carcinogenicity neither genotoxicity testing. Of the remaining 6 substances, 2 were 
combinations of known active ingredients; one substance was considered for minor use 
minor species/limited market (MUMS); 2 substances were considered clearly non-
genotoxic, with no structural alert and devoid of any potential carcinogenic risk: as in 
the case of Iitraconazole, it was shown to be devoid of mutagenic/genotoxic potential in 
a suitable battery of tests and the molecule had no structural alerts. One substance was 
considered similar to another one, authorized in the same period. For all the above 
entities, the carcinogenicity testing was fully waived.  
In vitro genotoxicity has been performed in approximately 38% of the substances in 
2011 and 17% in 2014, while in vivo studies of genotoxicity have been performed in 
33% and 11% of substances authorized in 2011 and 2014, respectively (Figure 11B).  
Detailed information from publicly available EPARs consulted for the analysis is reported 
in Annex III of this report. 
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Figure 11. Information on veterinary medicines. A) Total number of submissions and type of substances per year between 
2004 and 2014. B) Percent number of authorized new substances (excluding generics and biotechnology-derived 
medicines) that has undergone carcinogenicity, in vitro and in vivo genotoxicity testing in 2011 (n=21) and 2014 (n=18), as 
from EPARs documents. 
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3.7 Pesticides (EFSA) 
 
Pesticides are intended for the following uses: 1) protecting plants or plant products 
against all harmful organisms or preventing the action of such organisms; 2) influencing 
the life processes of plants, such as substances influencing their growth, other than as a 
nutrient (e.g. plant growth regulators, rooting hormones); 3) preserving plant products, 
(e.g. extending the life of cut flowers); 4) destroying undesired plants or parts of plants 
(e.g. herbicides/weed-killers to kill actively growing weeds); 5) checking or preventing 
undesired growth of plants. Approved active substance included in pesticides products 
may consist also in micro-organisms, pheromones and botanical extracts (bio-
pesticides). The most represented types of products are: fungicides, herbicides, 
insecticides, plant growth regulators, acaricides, etc. (Figure 12A). 
 
 
Figure 12. Information on pesticides. A) Represented product types, as percent of total, within the authorized substance 
list, available in DG SANTE PPPs DB. B) Total number of approvals and new active substances per year between 2004 and 
2014. C) Percent of authorized active substances that has undergone carcinogenicity, in vitro and in vivo genotoxicity 
testing in 2011 (n=48; new active substances=2) and 2014 (n=30; all new) (as from available DARs documents and 
pesticides database). 
The EU pesticide database, hosted on the DG SANTE website, collects information for 
1315 active substances: 474 approved, 788 not approved, of 33 the authorization of 
which is still pending, 20 substances banned (as on July 21, 2015). Up to present, 77 
active ingredients are on the list of candidates for substitution.  
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Within the last decade (2004-2014) there have been approximately 38 approvals per 
year on the European market, with an average of 10 new active substances each year 
(Figure 12B). It is worth noting that a significant increase of approvals, all related to 
renewals of existing substances, occurred in 2009 (n= 154). This probably reflects the 
introduction and updates of the 2009 Regulation on PPPs or CLP legislation earlier in 
2008. 
In 2011, exceptionally, 46 out 48 approvals regarded authorizations of pre-existent 
substances, undergoing re-evaluation. Only 2 new active substances were authorized 
and tested for carcinogenicity (2%) (Figure 12 B-C). 
Table 5. Carcinogenicity, in vitro and in vivo genotoxicity assessment in 2011. Percent number [%] of substances that 
were previously tested for carcinogenicity, in vitro and in vivo genotoxicity endpoints, as reported in the original dossier  
and actual percent number [%] of substances tested upon resubmission.  Far right column reports the percent number [%] 
of substances with no publicly available DAR. 
 
Upon resubmission, several tests, mainly related to genotoxicity in vitro (25%) and in 
vivo (31%), have been requested for update or confirmation of data. The 46 substances 
undergoing re-evaluation had been previously tested for carcinogenicity (83%) and 
genotoxicity (92%), as reported in the original dossiers (Table 5). 
In 2014, 57% of all new active substances have been tested for carcinogenicity (Figure 
11C), 73% and 65% for in vitro and in vivo genotoxicity, respectively. 
The opportunities for waiving the two-year bioassay study were limited to situations 
where, exposure was prevented or inexistent (treatments of ornamental plants) and 
clear negative results were obtained from sub-chronic or chronic toxicity tests and from 
tissues or organs in 90-days rat study.  
Pesticides that have been derived from natural sources including, natural chemicals, 
pheromones, bacteria, fungi and insect predators 6 are not tested for carcinogenicity. 
Often data from tier 1 tests suggest that those substances are not compatible with the 
                                           
6  Bio-pesticides can be described as crop protection products that have been derived from 
natural sources. They include naturally occurring chemicals, pheromones, bacteria, fungi and 
insect predators. Whilst in many instances the environmental risks of these substances is 
considered to be less than that of the more traditional chemical pesticides this is not always the 
case. Data to support risk assessments is scarce and currently there is no single, reliable 
comprehensive data source. The University of Hertfordshire is a source of data for both the more 
traditional agricultural pesticides (PPDB) and veterinary substances (VSDB). The University offers 
the BioPesticide DataBase (BPDB) which is a relational database of data relating to pesticides 
derived from natural substances. [University of Hertfordshire (2013) The Bio-Pesticides Database 
(BPDB) developed by the Agriculture & Environment Research Unit (AERU); 76] 
Testing in 2011 
Substances   
tested for  
Substances  not 
tested for  
DARs not 
available 
Studies reported  
in the Dossier for 
1^ submission 
Carcinogenicity 83.3 12.5 4.2 
In vitro genotox 91.7 4.2 4.2 
In vivo genotox 91.7 4.2 4.2 
     
Studies upon 
resubmission  
Carcinogenicity 2.1 93.8 4.2 
In vitro genotox 25.0 70.8 4.2 
In vivo genotox 31.3 64.6 4.2 
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mammalian cell environment, thus short, chronic or carcinogenicity studies have been 
considered irrelevant.  
In addition, for substances with extremely high toxicity, such as anticoagulants, 
chronic/carcinogenicity studies are not feasible (e.g. warfarin-like mode of action: high 
acute toxicity). 
Detailed information from publicly available DARs consulted for the analysis is reported 
in Annex IV of this report. 
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3.8 Cosmetics (DG SANTE, DG GROW) 
 
The two-year cancer bioassay had been rarely performed for testing cosmetic 
ingredients within the past 15 years. A combination of short term in vitro and in vivo 
studies has been used including in vitro and in vivo genotoxicity studies to assess 
genotoxic potential and repeat-dose toxicity studies (usually 90-day) to assess the risk 
of non-genotoxic chemicals, until 2009 [77].  
 
For the purpose of the present investigation, the Scientific Opinions publicly available on 
the SCCS website [78] and adopted between 2004 and 2014 were consulted (as on 
October 27, 2015).  
 
 
 
Figure 13. Information on cosmetics. A) Percent number of authorized cosmetic ingredients that has undergone 
carcinogenicity, in vitro and in vivo genotoxicity assessment between years 2004-2014. Data reported are based on 
Scientific Opinions published in 2004-2009 (n=63; revisions =23) and Scientific Opinions published within 2009-2015 (n=66; 
revisions 35) (as from publicly available SCCP and SCCS documents). B) Percent number of substances assessed for 
genotoxicity in in vivo tests between 2004 and 2014. 
 
 
Cosmetic products consist of between 5 to 60 ingredients each. Overall, it can be 
estimated that there are more than 20000 cosmetic ingredients globally (see CosIng list 
reported below). A recent document published by the European Commission [79], has 
reported that only 10% out of total cosmetic ingredients are submitted to the SCCS for a 
Scientific Opinion. In about 90% of the cases cosmetic ingredients are used in other 
sectors and fall under different regulations, including cosmetic products outside the EU, 
food, pharmaceuticals, and detergents that are covered by REACH. It has been 
estimated that the number of new ingredients added per year to the market is around 70 
for large suppliers and 22 for small medium enterprises (SMEs) between year 2000 and 
2009, representing around 4% of their ingredient portfolio. Roughly, new cosmetic 
ingredients are estimated to be 5 per manufacturer from large suppliers and 2-3 from 
SMEs, respectively [79]. 
 
At present (as from 20 December 2015), active cosmetic ingredients registered within 
the European Commission Database CosIng [80] are: 
 Ingredients & Fragrances: 24121 
 Ingredients prohibited (Annex II): 1378 
 Ingredients with restrictions (Annex III): 307 
 List of allowed colourants (Annex IV): 153 
 List of allowed preservatives (Annex V): 61 
 List of allowed UV filters (Annex VI): 28 
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In the present analysis, those chemicals with different applications other than the 
cosmetics for which other regulations can warrant in vivo testing (e.g. industrial use) 
were not considered.  
 
When consulting Safety Assessment Opinions from the last decade, the data on 
carcinogenicity were mainly references from literature or studies performed before 2004 
(Figure 13A). Interestingly, the two-year bioassay has not been carried out since 2003 
(two-year dermal in rat), ahead of full marketing ban on animal testing (March 2013). 
Nonetheless, safety assessment has included data from in vivo studies such as repeat-
dose (90-day) or toxicokinetics, as well as, in vivo genotoxicity testing until March 2013. 
The last in vivo genotoxicity studies were performed in 2011 (Figure 13B). 
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Discussion and Conclusions 
 
Marketed industrial chemicals, biocides, pesticides, human and veterinary medicines and 
cosmetic ingredients should be devoid, wherever possible, of toxic potential to humans 
or to the environment, including carcinogenic one and their toxicity should be well 
characterized in order to manage the risk and ensure an adequate degree of protection. 
Therefore, the carcinogenic hazard identification and characterisation represents an 
essential element of the safety assessment of any product manufactured, imported or 
sold in Europe and worldwide.  
Since its introduction in the late 60s, the two-year cancer study in rodents has been a 
requirement for testing carcinogenicity for any product authorization dossier. 
 
Currently, the two-year bioassay 
represents the 'gold standard' and 
since the first OECD Test Guideline 
release in 1981, the study has 
remained almost unaltered.   
Major modifications have applied, 
over the years, to the overall 
approach of carcinogenicity testing 
across the different product sectors, 
other than the study per se. The 
protocol, which specified the use of 3 
dose groups of animals, the highest 
being a maximum tolerated dose 
(MTD)7, with the focus of providing 
information on the possible health 
hazards likely to arise from repeated 
exposure for a period lasting up to 
the entire lifespan of the species used 
(objectives in the box) has been 
considered highly effective.  
Hence, as mentioned in paragraph 
3.1, the regulatory testing strategies 
for carcinogenicity have diversified 
significantly across the various 
legislations depending on the type of substance, the intended use and the level of 
exposure to humans and/or environment. However, two key elements have been 
maintained: testing for genotoxicity in vitro/in vivo and the two-year cancer study.  
For industrial chemicals, for instance, requirements are based on a tier-approach testing 
method and on the annual amount of substance production, to which potential exposure 
and degrees of exposure are linked. Carcinogenicity testing is required only for the high 
tonnage level and mainly for mutagens category 3.  
Extremely conservative requirements are in force and the testing of carcinogenicity is 
required for all the new pesticides and non-genotoxic new active biocides in two different 
species. For residues and metabolites the main concerns are also the exposure to very 
low doses that can persist for long periods of time and to occupational exposure. In 
those cases carcinogenicity is evaluated case-by-case.  
                                           
7 MTD was defined as the highest dose of a test substance used during the chronic study that can 
be predicted no to alter the animals normal longevity from effects other than carcinogenicity [81]. 
The objectives of carcinogenicity studies 
covered by test guidelines include: 
 
 The identification of the carcinogenic properties of a 
chemical, resulting in an increased incidence of 
neoplasms, increased proportion of malignant 
neoplasms or a reduction in the time to appearance of 
neoplasms, compared with concurrent control groups; 
 The identification of target organ(s) of carcinogenicity; 
 The identification of the time to appearance of 
neoplasms; 
 Characterisation of the tumour dose-response 
relationship; 
 Identification of a no-observed-adverse-effect level 
(NOAEL) or point of departure for 
 establishment of a Benchmark Dose (BMD); 
 Extrapolation of carcinogenic effects to low dose 
human exposure levels; 
 Provision of data to test hypotheses regarding mode of 
action.  
[OECD TG 451, 2009 update; (15)] 
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Of high concern are residues of veterinary drugs in food for human consumption 
(paragraph 3.1). It is a priority of this sector to rely on genotoxicity testing firstly and 
structural similarities, so positive results from those studies are further tested. Only 
when results from genotoxicity are clearly negative tests, no structure alerts are 
detected and the human exposure is negligible, carcinogenicity testing can be waived 
[57].  
 
Human medicines are commonly administered at high doses to reach the effective 
pharmacological dose, with short or chronic exposures. Usually carcinogenicity testing is 
performed mainly for all drugs for which a chronic administration is foreseen. In this 
case a test-battery approach is used starting always with genotoxicity in vitro followed 
by a thorough in vivo testing of genotoxicity and carcinogenicity.  
 
In contrast, no in vivo testing is allowed since March 2013 for cosmetic products [25] 
and carcinogenicity is predicted on the basis of alternative approaches only, relying 
mainly on in vitro genotoxicity studies.  
 
Diversification across regulations can be considered as a consequence of diversity in the 
human health risk in regard of each product use, of new products development, of 
raising economic issues and partly of 3Rs initiatives. The latter have promoted several 
changes within regulatory toxicology testing since their first legal embedment in the first 
EU Directive (1986) on animal welfare. According to the latest figures, there has been a 
minimal decrease in the animal testing burden used for cancer studies (at least until 
2011; Figure 4). In terms of absolute numbers this reduction could be regarded as 
negligible, as safety assessment of carcinogenicity per se is making use of fewer animals 
overall in comparison with other regulatory toxicity areas (e.g. acute, repro-, chronic, 
etc.), representing 1% of all toxicity testing (Figure 3C). However, in terms of animal 
welfare, a single two-year bioassay involves a large number of rodents, >600/study, it 
induces extended suffering, it implies a long-lasting period of data analysis and it has 
become extremely resource-consuming [77].  
 
A significant number of carcinogenicity studies are performed in the area of basic 
research, mainly within Academia [20], though it is hardly referred to the standard two-
year bioassay used for toxicological purposes. The ZEBET, the “Centre for 
Documentation and Evaluation of Alternative Methods to Animal Experiments”, part of 
the German Federal Institute for Risk Assessment (BfR) has released a database on the 
number of experimental procedures and relative animals proposed to be used in 
submitted projects in the last two years. In 2014, for instance, the use of 215000 
rodents approximately and 103 primates was estimated only for basic science projects 
related to cancer. 
In addition to animal welfare concerns, the relevance to humans of the two-year cancer 
study has been also questioned at length [30-32, 82]. Several investigations on 
medicinal products, for instance, have shown that the majority of tumour findings 
observed in rodent carcinogenicity studies are considered not to be relevant for several 
reasons: a) a rodent-specific mechanism of carcinogenicity; b) a high safety margin 
between exposures at the NOAEL (No Observed Adverse Effect Level) in rodents and 
recommended therapeutic doses in humans; c) based on historical control data; d) 
differences in metabolism/local concentrations between rodents and humans [83, 84]. 
The authors have shown that in total 65% of medicines tested for carcinogenicity in 
rodents result positive and among these findings, the majority are not relevant for 
humans (69/94, 73%). Similarly, Alden et al (2011) [17] found 80% of positive rodent 
cancer tests involving commercially available drugs (searched in the Physicians' Desk 
Reference Network, PDR) without concern for human risk. The above data were in line 
with previous reviews [85, 86].  
 
 42 
 
The resistance to the development and/or use of alternative (animal-free) approaches 
(in vitro tests, QSARs, structural alerts, mechanistic studies, read across, etc.) in this 
field has been mainly linked to technical difficulties of translating in vitro the whole 
process of carcinogenesis. Even in the presence of more elaborated in vitro tests, such 
as the cell transformation assay (CTA) or toxicogenomic-based tests [87-89]; the use of 
alternatives has been limited by concerns regarding the predictive capacity of these 
methods or the interpretation of data within the overall carcinogenicity assessment. 
Other concerns related to limited metabolic competences of the test systems, difficulty 
to discriminate genotoxic from non-genotoxic carcinogens or lack of mechanistic 
understanding [90]. Thus, carcinogenicity is far from being tested by only means of 
animal-free tests. It should be noted that several of the limitations explicitly highlighted 
for in vitro methods apply also to the animal carcinogenicity study.  
 
Data reviewed in this report have shown that the two-year bioassay is most frequently 
conducted within the pesticides sector (DAR reports information), even if a decrease of 
the number of substances tested likewise has been observed between year 20118 and 
2014. For most of the new active substances, a two-year rat bioassay study plus a 
combined chronic/carcinogenic rat study, often in combination with a second study in a 
second rodent species are conducted, even though the relevance of the latter has been 
questioned (Figure 11, Table 6) [91]. The PPPr Regulation foresees the use of alternative 
models to waive the second species though, this is rarely implemented. The 
carcinogenicity study is waived mainly on the basis of known limited human exposure 
risk, when it is technically not feasible, as in the case of some natural products or 
microorganisms, or on the basis of lack of genotoxicity effect of the substance (Table 6). 
In this regard, a conspicuous amount of substances are tested in in vivo genotoxicity 
studies. Each substance undergoes several genotoxicity tests: micronucleus, UDS study 
and COMET assay. 
Differently from pesticides sector, the use of alternative approaches has been observed 
more frequently in the biocides sector. The use of read-across data has been reported in 
several authorization dossiers for either the testing of carcinogenic potential or of the 
genotoxic one. Opportunities for waiving the carcinogenicity testing of biocidal products 
are similar to those described above for pesticides (Table 6). Overall, the two-year 
bioassay has been performed on 30% of products (Table 6). 
Within the pharmaceuticals sector, the introduction of specific shorter-term 
carcinogenicity studies as the transgenic mouse model agreed to be included in the 
ICHS1B guidance in 1997 [47], seemed at first to impact positively on the 3Rs. The use 
of P53+/- and the Tg.AC model, then the inclusion of the TgHras2, the XPA and 
XPAP53+/- murine genotypes [92] have shown promises for more technical specificity 
and impact on animal number. However, the transgenic model has resulted not to be a 
real reduction model, because of the amount of animals needed for the breeding of the 
specific knockout. It is worth noting that the use of transgenic animals has increased 
drastically in the recent years within the pharmaceuticals sector but especially in basic 
research [93]. 
 
Some modifications to the testing approach of human medicines have been included 
within the ICH guidance documents revisions [48-50] though, the latest versions are as 
for 1996 (S1A), 1997 (S1B), 2012 (S6 and revised S1 Concept Paper and Business 
Plan). Some 'opportunities/justifications' for waiving the cancer study include intrinsic 
product hazard, human health risk, risk/benefits ratios, the final use of medicine or the 
patient health status. However, in 2014, a substantial portion of authorized human 
medicines have undergone carcinogenicity testing and the use of only alternative 
approaches has been rarely considered.  
                                           
8 Data collected from 2011 authorizations were mainly re-submissions (see paragraph 3.5) 
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Within this sector, the two-year bioassay is not conducted for specific classes of 
therapeutic/diagnostic agents when it is not scientifically relevant or technically feasible 
(Table 6). For instance, none of the products authorized for veterinary use in 2014 have 
been tested for carcinogenicity, only because they were vaccines and biotechnology-
derived proteins. Only few of them had known non-genotoxic non-carcinogenic potential 
(Table 6).  
 
Table 6. Carcinogenicity testing across sectors in 2014. Percent number of authorized substances tested for 
carcinogenicity and type of justifications considered for waiving the testing: snapshot of 2014 situation. 
 
                                           
9 Estimate from EC Impact Assessment (2013) [79]. 
Sector 
Substances 
tested for 
carcinogenicity 
in 2014 
Substances 
authorized or 
registered in 2014 
Waiving of carcinogenicity testing 
 is justified when: 
Pesticides 66.7% 30 
natural products,  
highly toxic compounds: warfarin-like, 
short-exposure to humans (products for ornamental 
plants), 
microorganisms (incompatible with mammalian cell 
environment; the study is not feasible), 
short effect, not genotoxic,  
inexistent risk of exposure 
target (plant) not for human consumption  
Biocides 33.3% 12 
negligible secondary human exposure, 
very low primary exposure, 
lack of substance related non-genotoxic and 
genotoxic effect, 
satisfactory MOE and absence of structural alert,  
availability of read-across data  
Human 
medicines 
42.2% 
65  
(69 % new entities 
=45) 
antibodies,  
recombinant proteins, vaccines, 
generics, biosimilars, 
 anti-cancer drugs,  
very short-term treatments,  
life-threatening treatments,   
extremely short patient's life expectancy,  
dossiers were presented to other authorities (FDA or 
Japan) 
Some of the studies will be performed post-
authorization. 
Veterinary 
medicines 
0.0% 
18  
(67% vaccines) 
justifications similar to human drugs 
Chemicals 
(REACH) 
0.0% (2 only) 
>3000 
1600 exp. studies 
(>1000 tons/yr) 
[data refer to the 2013 deadline registration, mainly 
old chemicals; up to date, only 2 cancer studies have 
been performed]  
Cosmetics 0.0% 
7-10 approx.
9
  
(10-15 SCCS 
Opinions) 
n.a. 
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Of interest is the proposal to change the actual testing approach for rodent 
carcinogenicity (ICHS1 guideline) which is summarized in the latest Status Report of 
Regulatory Notice Document [52]. The new concept, formulated by the ICHS1 Expert 
Working Group, is based on the hypothesis that: 'a weight of evidence evaluation can, in 
certain cases provide sufficient information to conclude that a given pharmaceutical 
presents a negligible risk or, conversely, a likely risk of human carcinogenicity without 
conducting a two-year rat carcinogenicity study'. The weight of evidence includes but is 
not limited to, data from chronic toxicity studies, genotoxicity and pharmacology. The 
rationale behind this proposal has been supported by a retrospective evaluation of 
several datasets from Industry and Drug Regulatory Agencies (DRAs) which suggests 
that up to 40% rat cancer studies might be avoided by integrating data from (6-month) 
chronic rat studies, evidence of hormonal perturbation and genotoxic profile in the 
standard battery [84, 94]. In addition, the knowledge on the pharmacological properties 
of the compounds, together with the histopathology findings from the chronic toxicity 
study in rodents may allow to define conditions under which the two-year rat 
carcinogenicity studies will or will not add value to the toxicology profile [95]. A 
prospective evaluation study to confirm the above hypothesis is undergoing [52]. The 
sponsors are invited, on a voluntary base, to submit to DRAs a Carcinogenicity 
Assessment Document (CAD) to address the carcinogenic potential of an investigational 
pharmaceutical and predict the outcome and value of the planned two-year rat 
carcinogenicity study and eventually claim a virtual waiver. A decisional analysis based 
on the outcomes from this exercise is expected by the end of 2019. Positive outcome 
from this exercise could infer the classic way of approaching the testing of 
carcinogenicity and might yield a significant reduction in the two-year cancer study 
conduct.  
Since the first registration deadline of the REACH Regulation [38] in 2009, only two 
industrial chemicals have been tested for carcinogenicity, following acceptance of the 
testing proposal by ECHA. These chemicals were among those of high tonnage level 
registered within 2013 deadline for which, the majority of the dossiers reported 
information from references and old literature. New carcinogenicity studies are not 
expected to be conducted for the 2018 deadline registration due to reduced testing 
requirements for lower tonnage band chemicals. Though, new phase-in substances may 
be registered for which carcinogenicity assessment should be considered. 
Finally, the impact of carcinogenicity testing on the authorization of substances has been 
null within the cosmetics sector. Yet, no cancer study has been performed since 2003, 
ten years ahead the full ban of in vivo testing of March 2013, (Figure 12, Table 6). In 
fact, a combination of shorter-term in vitro and in vivo studies has been used including 
in vitro and in vivo genotoxicity assays, to assess genotoxic potential and repeat-dose 
(typically 90-day) toxicity studies to assess the risk of non-genotoxic chemicals [77]. 
 
 
What can we learn from waiving opportunities? Can they be applied across sectors or are 
they sector-specific due to the specific use of each substance? The data reported here 
have shown differences across sectors in testing approaches but also in the demand of 
carcinogenicity studies, the number of animals used and the opportunities for waiving 
the two-year study. As summarised in Table 6, some waivers are put in place for certain 
types of substances. Waivers are often supported by the absence of structural alerts and 
lack of genotoxic potential and/or specific properties. Though, risk-based information 
regarding destination of use, target population and foreseen exposure levels are also 
considered and these vary substantially across sectors. Moreover, different Regulations 
with specific testing requirements and levels of concerns are in place. For instance, the 
EU pesticides law forbids the marketing of active substances which can cause cancer, 
while for certain types of medicines instead, an intrinsic carcinogenic potential may be 
tolerated. At present, it is rather difficult to apply similar waiving conditions across 
sectors. It is thus recommended to explore whether existing waiving opportunities can 
 45 
 
be further exploited and applied cross-sectorial. Where possible, this might imply the 
need for a better harmonization of regulatory requirements and testing strategies in 
different areas. 
 
The recourse to approaches alternative to animal testing is also quite variable across 
sectors. Unfortunately, their application is far to be systematic, even though several 
testing approaches are being explored in recent years, as in the case of human 
medicines or of some regulations which are calling for their use. 
The analysis highlights also that a substantial portion of new substances, such as bio-
pesticides and new drugs (biotechnology-derived ones) entering on the market, bear 
specific features that make their testing not technically feasible with the current 
available methods. This makes their safety characterisation rather difficult. The 
introduction of these new types of products is bringing regulatory and technical 
challenges for a correct safety evaluation that needs to be addressed accordingly with 
new tools. Several groups have recently highlighted the need for improvements of 
carcinogenicity assessment with the scope of harmonize strategies and advancing the 
3Rs across sectors [90, 92, and 96]. Results from our study suggest a similar direction 
of efforts.  
It might be worthwhile to look to different toxicity areas as to systemic toxicity, 
immunotoxicity and the area of sensitization. Many of the same mechanisms are 
involved in either endpoint [77, 97]. This can also help building accurate pathways as 
adverse outcome pathways (AOP) to recapitulate the mechanism of cancer toxicity at 
different levels.  
Of note is also the recent exercise from an IARC Working group of experts on the 
identification of key characteristics which can provide the basis for an objective 
evaluation of hazard from exposure to carcinogens [98]. Ten key characteristics have 
been identified so far and they imply indeed abilities of agents that can: act as an 
electrophile; act as genotoxic; alter DNA repair mechanisms; induce epigenetic 
alterations, chronic inflammation; oxidative stress; immune-suppression; modulate 
receptor-mediated effects; cause immortalization; alter cell proliferation, death or 
nutrient supply [98]. The above characteristics might serve for the design of more 
accurate and predictive test methods, which would also cover non-genotoxic 
mechanisms.  
 
In this direction is the recent activity regarding non-genotoxic carcinogens carried at 
international level by The Organisation for Economic Co-operation and Development 
(OECD) expert group on non-genotoxic carcinogenicity on the development of Integrated 
Approaches to Testing and Assessment (IATA).  There is a wide gap in the area of non-
genotoxic carcinogens identification due to the differences in regulatory requirements 
across sectors and lack of specific validated/authorized test methods; especially, in the 
area of cosmetics and industrial chemicals of low tonnage band. Mechanistic 
understanding needs to be built upon as soon as possible [77]. In fact, the aim of the 
initiative is to identify relevant appropriate carcinogenicity mechanisms, MoAs, and 
assays which would be appropriate for the development of an IATA. Aspects/blocks of 
the signalling pathways that are not covered and would require further development will 
also be identified. 
 
Promising modelling applications of toxicogenomics, have been recently developed to 
capture specific gene expression changes observed for non-genotoxic carcinogens [99]. 
Together with toxicogenomics, exposomics, metabolomics and epigenomics areas 
represent emerging tools that may contribute in the future to the improved assessment 
of safety [100]. According to that, it might be worthwhile to exploit the advances in the 
characterization of the human genome and whole genome sequencing, which can inform 
on the distinct pattern of mutations that can hint at the causative origins of each type of 
cancer. Consequently, the study of various mutations spectra induced by different 
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environmental mutagens can serve as a platform to better characterize those agents 
responsible for specific human tumours [101]. 
 
Interestingly, new approaches are currently being tested as new way of identifying 
chemicals that may increase specific cancer risk. For instance the Hazard Identification 
Approach for Breast Carcinogens (HIA-BC) project which has been developed to detect 
those chemicals that may increase specifically breast-cancer risk [102]. The project 
identifies those assays capable of detecting alterations to biological processes relevant to 
breast cancer, including, molecular, cellular events, tissues changes and factors altering 
the susceptibility to the disease. 
It is foreseen that the above tools and approaches could provide opportunities to add 
knowledge to the characterization of cancer and safety evaluation of environmental 
carcinogens and could also result more relevant to humans. 
 
Overall, the analysis conducted here suggests that the following objectives should be 
pursued with the aim of further improving carcinogenicity assessment and reducing 
animal testing:  
 
 sharing experiences and approaches across sectors and explore if they are 
applicable to different sectors; 
  
 developing alternative approaches to ensure an accurate carcinogenicity hazard 
assessment where it is technically limited or in areas where in vivo testing is 
limited  (e.g. cosmetics or industrial chemicals of lower tonnage band) or where 
information gaps are identified within legislations; 
 
 integrating information provided by other toxicity endpoints into carcinogenicity 
assessment. 
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Annexes 
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documents from EMA website. Data refer to year 2011 and year 2014. 
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Annex I.  Biocides list of authorized substances in 2011 and 2014 
 Substance Category  Carcinogenicity Studies  In vitro genotox studies  In vivo genotox studies 
Date of 
approval 
1 Metofluthrin 
Insecticides, 
acaricides and 
products to 
control other 
arthropods 
yes 
combined chronic/CARC study in rats, 
and chronic/CARC study in mice 
yes 
AMES, CA in CH ling cells, HGPRT in CHO 
cells, 
yes 
MN vivo mice PCEs, 2^ study in 
vivo germ cells waived 
01/05/2011 
2 Alphachloralose Rodenticides no waived yes AMES, CA, MLA, HPRT no waived 01/07/2011 
3 Bromadiolone Rodenticides no waived yes AMES, CA in CHO, HPRT in CHO no waived 01/07/2011 
4 Chlorophacinone Rodenticides no 
The closely related molecule warfarin is 
not carcinogenic to humans. Study on 
chlorophacinone is not available. 
Carcinogenicity and long-term toxicity 
studies are not submitted and Applicant 
present a justification on the basis of 
the knowledge of mechanism of toxicity 
and technical difficulties to test so low 
dose needed for a long term exposure 
without lethality.  
yes AMES, CA, MLA yes MN vivo in mice 01/07/2011 
5 Coumatetralyl Rodenticides no 
waived, because non genotoxic, no 
metabolites, similar to warfarin 
yes 
AMES, Rec –assay in S. cerevisiae,  HPRT in 
V79cells, CA waived 
yes 
MN vivo in mice BM, 2^ in vivo 
waived 
01/07/2011 
6 Fenpropimorph 
Wood 
preservatives 
yes 
1-combined chronic/CARC study in 
rats, one 2-yrs in mice, 2-yr study mice 
yes  yes  01/07/2011 
7 Sulfuryl fluoride* 
Insecticides, 
acaricides and 
products to 
control other 
arthropods 
 
2-yr study per inhalation in rats; 18-M 
and 12-M in mice;1 study with various 
species  
 
AMES (E.coli, S. typhimurium.), CA vitro, UDS 
vitro, MLA vitro 
 MN vivo; 2^ study in vivo waived 01/07/2011 
8 
Aluminium 
phosphide 
releasing 
phosphine 
Rodenticides yes 
2-yr study per inhalation in rats; waived 
2^ study in mice 
yes  yes  01/09/2011 
9 Boric acid 
Wood 
preservatives 
yes 
2-yrstudy, feeding, in rats; waived 2^ 
species study 
yes AMES, CA in CHO, MLA all negatives no 
waived because negative in vitro 
and IUCLID reports -ve in vivo 
study 
01/09/2011 
10 Boric oxide 
Wood 
preservatives 
read across with boric acid 01/09/2011 
11 
Disodium 
octaborate 
tetrahydrate 
Wood 
preservatives 
read across with boric acid 01/09/2011 
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[continue] 
 Substance Category  Carcinogenicity Studies  In vitro genotox studies  In vivo genotox studies 
Date of 
approval 
12 
Disodium 
tetraborate 
Wood 
preservatives 
read across with boric acid 01/09/2011 
13
 
Disodium 
tetraborate 
decahydrate 
Wood 
preservatives read across with boric acid
 01/09/2011 
14
 
Disodium 
tetraborate 
pentahydrate 
Wood 
preservatives read across with boric acid
 01/09/2011 
15
 
Nitrogen 
Insecticides, 
acaricides and 
products to 
control other 
arthropods 
not applicable  01/09/2011 
16
 
Flocoumafen Rodenticides no 
Waived; refine waiving concept based 
on exposure pattern and toxicological 
profile. Negligible secondary human 
exposure, very low primary exposure, 
anticipated lack of substance related 
non-genotoxic and genotoxic effect 
anticipated satisfactory MOE and 
absence of structural alert. 
yes AMES, CA in rats liver cells, HPRT in V79 
cells, CTA supporting study  yes 
CA in vivo BM cells, 2^ in vivo 
study waived because negative 
in other studies, waived also 
genotoxicity study in germ cells 
01/10/2011 
17
 
Tolylfluanid Wood preservatives yes
 
2-yr combined chronic/CARC study in 
rats  TG 453 and TG 452 study in dogs; 
2-yr mouse study in B6CF and 2-yr 
study in NMR1 mice TG 451 
yes AMES and HPTR in CHO); CA in CHL cells; MLA tk mouse; UDS in rat liver primary cells : 
Negative results yes
 MN, CA, Mouse Spot test, mouse spermatogonia test TG 483:  
negative result 01/10/2011 
 
Legend 
CA:  chromosomal aberrations assays 
MLA:  mouse lymphoma assay mammalian cell gene mutation using Tk gene 
HPRT/HGPRT: mammalian Cell gene mutation using the Hprt and Xprt genes 
MN:  micronucleus test 
UDS: Unscheduled DNA Synthesis 
CHO: Chinese hamster ovary cells 
CHL: Chinese hamster lung cells 
PCEs:  polychromatic erythrocytes 
BM: bone marrow  
COMET: DNA damage (COMET assay) 
DML:  Dominant lethal assay in rodent 
The information reported was retrieved from ECHA biocides website and related documents where available. 
*sulfuryl fluoride was tested for a different authorization (as wood preservative) right in 2009.  
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 Substance Category  Carcinogenicity Studies  In vitro genotox studies  In vivo genotox studies 
Date of 
approval 
1
 
Basic Copper 
carbonate 
 Wood 
preservatives no
 short-term study only, waived the 2-yr 
studies for non genotoxic potential yes AMES study yes MN vivo, UDS vivo 01/02/2014 
2
 
Bendiocarb 
Insecticides, 
acaricides and 
products to 
control other 
arthropods 
yes 2-yr studies in rats  and mice yes AMES, CA in human lymphocytes, UDS in 
HeLa cells, MLA  yes MN in CD-1 mice PCEs cells, CA in BM, rodent DML 01/02/2014 
3
 
Copper (II) oxide Wood preservatives read across with copper (II) sulphate pentahydrate
 01/02/2014 
4
 
Copper 
hydroxide 
Wood 
preservatives yes
 Short-term study only, waived the 2-yr 
studies for non genotoxic potential yes AMES, UDS yes  MN in PCEs of BM mice, UDS in rat hepatocytes 01/02/2014 
5
 
Flufenoxuron  Wood preservatives yes
  2-yr rat study; two 2-yr mouse studies yes AMES, CA, MLA yes CA in rat BM, MN vivo in mouse 
BM, UDS in rat liver 01/02/2014 
6
 
Hydrochloric 
acid 
Disinfectants 
and 
algaecides not 
intended for 
direct 
application to 
humans or 
animals 
no Supporting information from IARC 
reported study yes 
 AMES Salmonella only, recombination test in 
Yeast, E. coli pol-A repair test, CA in CHO, 
MLA no
 waived - because scientifically 
unjustified 01/05/2014 
7
 
Margosa extract 
 Insecticides, 
acaricides and 
products to 
control other 
arthropods 
yes 2-yr study in rats only, waived the 2^ 
study in mice  yes AMES, CA in human lymphocytes, HPRT in CHO cells yes MN in BM mice, 2^ test waived 01/05/2014 
8
 
Methyl nonyl 
ketone 
Repellents 
and 
attractants 
no read across with other aliphatic ketons yes AMES, CA, MLA no waived - because scientifically 
unjustified 01/05/2014 
9
 
cis-Tricos-9-ene 
(Muscalure) 
Repellents 
and 
attractants 
no waived yes AMES, CA,  QSARs from OECD toolbox no waived, some data from literature 
but used as informative only 01/10/2014 
10
 
Hydrogen 
cyanide 
Wood 
preservatives no
 literature reported documents no literature reported documents no literature only 01/10/2014 
11
 
Hydrogen 
cyanide Rodenticides similar
 literature reported documents no literature reported documents no literature only 01/10/2014 
12
 
Hydrogen 
cyanide 
Insecticides, 
acaricides and 
products to 
control other 
arthropods 
similar literature reported documents no literature reported documents no literature only 01/10/2014 
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Annex II.  Human medicines list of authorized substances in 2011 and 2014 
 Name  
Active 
ingredient 
Cat. Rev. Carcinogenicity Studies 
in vitro Genotox 
studies 
in vivo Genotox studies 
Date of 
approval 
1
 
Ameluz (5-aminolevulinic 
acid  HCl) unique entity 4
 
No CARC studies 
Topical therapy with Ameluz 10% is limited to a single 
application of the gel to lesional skin and ALA-PDT is an 
established treatment for AK. Therefore, the lack of 
carcinogenicity studies is considered to be acceptable 
No studies were conducted by the applicant on the mutagenic and 
clastogenic potential of ALA or PpIX as part of the development 
program for Ameluz. Based on published data, the likelihood of 
sustained genetic damage in surviving cells after ALA-PDT is 
considered to be low (Fuchs et al., 2000). 
14/12/2011 
2
 
Benlysta belimumab unique 
entity 10
 
No CARC studies have been conducted. A traditional 
rodent carcinogenicity study would be limited due to rapid 
formation of anti-drug-antibodies to both belimumab and a 
homologous hamster anti-mouse BLyS antibody. A study 
in BLyS ko mice for pre-neoplastic changes would not be 
a representative model as mice deficient in BLyS or the 
main BLyS receptor B3, have severely depleted numbers 
of peripheral B cells while belimumab treatment in 
humans reduces peripheral B cell populations by 50% but 
does not deplete them. No proliferative or pre-neoplastic 
changes were reported in any of the monkeys in a 6 
month repeat dose toxicity study. 
No genotoxicity studies were conducted. Belimumab is a monoclonal 
antibody and is not expected to interact directly with DNA or other 
chromosomal material.  
Regulatory guidance is consistent with studies on genotoxicity not 
being necessary for this type of product. 
13/07/2011 
3
 
Buccolam midazolam unique 
entity 4
 2-yr CARC studies in mice and rats Tested in vitro and in vivo 05/09/2011 
4
 
Bydureon exenatide unique 
entity 5
 2-yr CARC study in rats with exenatide QW, previously 
done on a different formulation in mice and rats Tested in vitro and in vivo 17/06/2011 
5
 
Cinryze C1 inhibitor – 
human unique entity 8
 
Only human study 
A highly purified, viral-inactivated, nano filtered 
concentrate of C1 esterase inhibitor (C1 INH) produced 
from human plasma 
No genotoxicity testing 15/06/2011 
6
 
Clopidogrel 
Teva Pharma 
B.V.  clopidogrel HBr
 generic 3 On the basis of the CHMP Guidance for users of the centralised procedure for generic application (EMEA/CHMP/225411/2006), no studies were performed 
16/06/2011 
No longer 
authorized 
7
 
Daliresp roflumilast unique 
entity 5
 Since this application is an informed consent of the Daxas marketing authorisation, the non-clinical data in support of the Daliresp application are identical to the up-to-date non-clinical data of the Daxas dossier, which have been assessed and approved (including 
all post-marketing procedures). 28/02/2011
 
8
 
Dasselta desloratidine generic 3 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and 
adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The 
impurity profile has been discussed and was considered acceptable. 
28/11/2011 
9
 
Desloratadine 
Teva desloratiden generic 3 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and 
adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The 
impurity profile has been discussed and was considered acceptable. 
24/11/2011 
10
 
Dexdor dexmedetomide 
HCl unique entity 3
 No CARC studies were performed and this can be considered acceptable in view of the proposed and 
anticipated maximum duration of treatment (14 days). Tested in vitro and in vivo 
16/09/2011 
 
 
 63 
 
[continue] 
 Name  
Active 
ingredient 
Cat. Rev. Carcinogenicity Studies in vitro Genotox studies in vivo Genotox studies 
Date of 
approval 
11
 
Edurant rilpivirine HCl unique 
entity 6
 2-yr CARC studies in mice and rats Tested in vitro and in vivo 28/11/2011 
12
 
Eliquis apixaban unique 
entity 4
 2-yr CARC studies in mice and rats Tested in vitro and in vivo 18/05/2011 
13
 
Entacapone 
Orion entacapone unique entity 3
 
Informed consent of the Comtess application, the non-
clinical data in support of the Entacapone Orion application 
are identical to the up-to-date non-clinical data of the 
Comtess dossier, 
No genotoxicity testing 18/08/2011 
14
 
Entacapone 
Teva entacapone generic 5 Toxicology is based on literature searches and adequate scientific literature has been provided No genotoxicity testing 18/02/2011 
15
 
Esbriet pirfenidone orphan 10 2-yr CARC study rats and mice 
 
and  mechanistic  hepatic assays in rats and mice Tested in vitro and in vivo 28/02/2011 
16
 
Eurartesim piperaquine tetraphosphate 
/dihydroartemisinin 
unique 
entity 3
 
No data is available in the literature on the carcinogenicity 
of DHA or PQP or the combination. As treatment is only 
intended to be given for three days, carcinogenicity tests 
are not required. 
Tested in vitro only 27/10/2011 
17
 
Eviplera 
emtricitabine / 
rilpivirine 
hydrochloride 
/tenofovir 
disoproxil fumarate 
unique 
entity 9
 2-yr CARC study in rats and mice Tested in vitro and in vivo 28/11/2011 
18
 
Fampyra fampridine unique 
entity 5
 2-yr CARC study in rats and mice Tested in vitro and in vivo 20/07/2011 
19
 
Gilenya fingolimod 
hydrochloride unique entity 9
 2-yr CARC study in rats and mice Tested in vitro and in vivo 17/03/2011 
20
 
Halaven eribulin unique 
entity 7
 As anti-cancer drug, no carcinogenicity  study was 
performed Tested in vitro and in vivo 17/03/2011 
21
 
Hizentra human normal immunoglobulin 
(SCIg) 
unique 
entity 10
 Human immunoglobulins are naturally occurring proteins with well-established safety and tolerability not required toxicity studies 14/04/2011 
22
 
Iasibon ibandronic acid generic 3 Toxicological properties of ibandronic acid are well characterised. An overview based on the literature was considered appropriate 21/01/2011 
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23
 
Dificlir fidaxomicin unique 
entity 6 
No CARC studies  
Considering the short (10 days) planned duration of dosing, 
carcinogenicity studies were not conducted with fidaxomicin. Tested in vitro and in vivo
 05/12/2011 
24
 
Edarbi azilsartan 
medoxomil unique entity 3 
2-yr CARC studies were performed with TAK-491 in rats and 
with TAK-536 in mice and rats  
A 26-week carcinogenicity study was performed with TAK-
491 in transgenic mice 
Tested in vitro and in vivo 07/12/2011 
25
 
Ibandronic Acid 
Sandoz 
ibandronic acid 
irbesartan / 
hydrochlorothiazide generic 2 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product.
 26/07/2011 
26
 
Ifirmacombi ibandronic acid
 
irbesartan / 
hydrochlorothiazide generic 3 
Generic application referring to the originator product CoAprovel, no new non-clinical studies on the pharmacology, 
pharmacokinetics and toxicology of irbesartan and hydrochlorothiazide have been undertaken 04/03/2011 
27
 
Incivo telaprevir unique 
entity 16
 Since the duration of treatment is limited to 12 weeks and no concern for carcinogenicity have been observed during toxicity 
testing, carcinogenicity studies for Telaprevir were deemed unnecessary. As well as genotoxicity studies 19/09/2011 
28
 
Jevtana cabazitaxel unique 
entity 9
 
According to the ICH Topic S9, carcinogenicity study is not 
required to support marketing for therapeutics intended to 
treat patients with advanced cancer, but cabazitaxel can be 
considered as a carcinogenic agent due to the genotoxic 
properties 
Tested in vitro and in vivo 17/03/2011 
29
 
Komboglyze 
metformin 
hydrochloride 
/saxagliptin 
hydrochloride 
unique 
entity 6
 Extensive clinical experience does not indicate a relevance for humans. Consequently, further studies on the combination 
product were not necessary and the combination saxagliptin/metformin has not been tested for carcinogenicity 24/11/2011 
30
 
Lamivudine/Zidovudine 
Teva lamivudine / zidovudine generic 5 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. There is thus no need for conducting tests on animals. 28/02/2011 
31
 
Leganto rotigotine unique 
entity 6
 It is an informed consent of the Neupro application, the non-clinical data in support of the Leganto application are identical to 
the up-to-date non-clinical data of the Neupro dossier 16/06/2011 
32
 
Levetiracetam Accord levetiracetam generic 4 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No toxicity testing 03/10/2011 
33
 
Levetiracetam Actavis levetiracetam generic 5 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No toxicity testing 03/10/2011 
34
 
Levetiracetam Actavis 
Group levetiracetam generic 3 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No toxicity testing 05/12/2011 
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35
 
Levetiracetam ratiopharm levetiracetam generic 4 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No genotoxicity testing 26/08/2011 
36
 
Levetiracetam Sun levetiracetam generic 5 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No genotoxicity testing 14/12/2011 
37
 
Levetiracetam Teva levetiracetam generic 7 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No genotoxicity testing 26/08/2011 
38
 
Levodopa/Carbidopa/Entaca
pone Orion levodopa / carbidopa /entacapone unique entity 4
 
Informed consent of the Stalevo application, the non-clinical 
data in support of the Levodopa/Carbidopa/Entacapone 
application are identical to the up-to-date non-clinical data of 
the Stalevo dossier, 
No genotoxicity testing 24/08/2011 
39
 
Libertek roflumilast unique 
entity 5
 
Informed consent of the Daxas marketing authorisation, the 
non-clinical data in support of the Libertek application are 
identical to the up-to-date non-clinical data of the Daxas 
dossier, 
No genotoxicity testing 28/02/2011 
40
 
Matever levetiracetam generic 11 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. No genotoxicity testing 03/10/2011 
41
 
Methylthioninium chloride 
Proveblue methylthioninium chloride generic 7 Literature only AMES test only 06/05/2011 
42
 
Nulojix belatacept unique 
entity 3
 
No carcinogenicity testing.  
A lifetime study (study nr 97610) in mice was conducted with 
abatacept to determine the carcinogenic potential of CD28 
blockade 
Genotoxicity testing is generally not required for 
protein therapeutics. No genotoxicity studies were 
conducted with belatacept. However, a battery of 
validated in vitro genotoxicity assays was conducted 
with similar abatacept. 
17/06/2011 
43
 
Plenadren hydrocortisone orphan 3 No testing 03/11/2011 
44
 
Potactasol topotecan generic 0 
Topotecan was described as genotoxic to mammalian cells. Long-term carcinogenicity studies with topotecan were not 
submitted. According to CPMP/SWP/997/96, “Note for Guidance on the pre-clinical evaluation of anticancer medicinal 
products” this is acceptable, because carcinogenicity studies are not usually required due to the intended therapeutic 
indications. However, topotecan is known to be genotoxic to mammalian cells and is probable carcinogen. 
06/01/2011 
45
 
Pramipexole Accord pramipexole dihydrochloride 
monohydrate generic 2
 The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. 30/09/2011 
46
 
Pravafenix fenofibrate / 
pravastatin unique entity 2
 No new studies have been performed, which is acceptable according to the current guideline: The Non-Clinical 
Development of Fixed Combinations of Medicinal Products (EMEA/CHMP/SWP/258498/2005). 14/04/2011 
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47 Pumarix 
pandemic influenza 
vaccine (H5N1) (split 
virion, inactivated) 
Exceptional 
Circumstan
ce 
4 
No CARC studies were performed according to the Note for 
Guidance on preclinical pharmacological and toxicological 
testing of vaccines (CPMP/SWP/465/95 guidance) and the 
Guideline on adjuvants in vaccines for human use 
(EMEA/CHMP/ VEG/134716/2004). 
Genotoxicity of the adjuvant alone was assessed in two 
in vitro tests (reverse mutation (Ames) test in bacteria; 
gene mutation in mouse cells) and one in vivo test 
(micronucleus test in the rat after intravenous 
administration). The vaccine was not tested. No 
indication of genotoxicity was evident. 
04/03/2011 
48 Rasilamlo aliskiren / amlodipine 
unique  
entity 
4 
No CARC studies were conducted with Rasilamlo since this 
area has been adequately investigated for the 
monocomponents 
Tested in vitro only 14/04/2011 
49 Repaglinide Accord repaglinide generic 1 
The non-clinical aspects of the SmPC are in line with the 
SmPC of the reference product. 
No genotoxicity testing 22/12/2011 
50 Repso leflunomide generic 7 
Relevant non-clinical safety data for Repso have been 
summarized in a non-clinical overview and included in section 
5.3 of the SmPC which is identical to the texts of the reference 
medicinal product Arava. 
No genotoxicity testing 14/03/2011 
51 
Rivastigmine 
Actavis 
rivastigmine 
hydrogen tartrate 
generic 7 
The non-clinical aspects of the SmPC are in line with the 
SmPC of the reference product. 
No genotoxicity testing 16/06/2011 
52 
Telmisartan Teva 
Pharma 
telmisartan generic 3 
Because Telmisartan Teva Pharma is a generic medicine, 
studies in patients have been limited to tests to determine that 
it is bioequivalent to the reference medicine, Micardis. Two 
medicines are bioequivalent when they produce the same 
levels of the active substance in the body 
No genotoxicity testing 03/10/2011 
53 Temozolomide Sun temozolomide generic 6 Six cycle in rats only Tested in vitro only 13/07/2011 
54 Teysuno 
tegafur / gimeracil / 
oteracil 
unique  
entity 
8 
The 2-yr CARC studies in both mice and rats were both 
preceded by dose range finding studies of 4 week duration in 
the mouse and 13-week duration in both the mouse and  rat 
Tested in vitro and in vivo 14/03/2011 
55 Tobi Podhaler tobramycin orphan 4 
No CARC study with TIP was performed. However in a 95-
week carcinogenicity study in rats with the TOBI inhalation 
formulation, no evidence of a carcinogenic potential was seen 
No genotoxicity testing 20/07/2011 
56 Trajenta linagliptin 
unique  
entity 
4 2-yr CARC study in rats and mice Tested in vitro and in vivo 24/08/2011 
57 Trobalt 
pandemic influenza 
vaccine (H5N1) (split 
virion, inactivated) 
unique  
entity 
8 
2-yr CARC study in rats + 1 study neonatal carc in mice pnd8-
pnd15 gavage treatment 
Tested in vitro and in vivo 28/03/2011 
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58
 
Vibativ telavancin unique  
entity 5
 Treatment of telavancin is expected to be up to 21 days and the need for carcinogenicity testing is only required for drugs 
administered for at least 6 months. Tested in vitro and in vivo
 02/09/2011 
59
 
Victrelis boceprevir unique  
entity 16
 2-yr CARC study in rats and mice Tested in vitro and in vivo 18/07/2011 
60
 
Votubia everolimus orphan   11 2-yr CARC study in rats and mice Tested in vitro and in vivo 02/09/2011 
61
 
Vyndaqel tafamidis 
orphan - 
exceptional 
circumstanc
es 
5 A 26-week CARC study in transgenic rasH2 mice was 
conducted by the oral (gavage) route of administration Tested in vitro and in vivo 16/11/2011 
62
 
Xeplion paliperidone 
palmitate unique  entity 5
 2-yr CARC study in rats only Tested in vitro only 04/03/2011 
63
 
Xgeva denosumab unique  
entity 4
 
No specific studies were conducted. Denosumab is a 
recombinant protein and contains no inorganic or synthetic 
organic linkages or other non-protein portions. Regulatory 
guidance is consistent with studies on genotoxicity not being 
necessary for this type of product 
No genotoxicity testing 13/07/2011 
64
 
Xiapex collagenase Clostridium 
histolyticum 
unique  
entity 10
 
In accordance with ICH guidance (ICH, 1995 and ICH, 1997) 
carcinogenicity studies with AA4500 were not conducted. ICH 
(1997) indicates that standard carcinogenicity bioassays are 
generally not required for biotechnology derived 
pharmaceuticals, particularly proteins with no known growth 
factor activity. 
Tested in vitro and in vivo 28/02/2011 
65
 
Yellox bromfenac sodium 
sesquihydrate unique  entity 3
 
In line with ICH S1A, CARC studies are not warranted for 
Yellox, since it will be indicated for a treatment period of only 
two weeks, and there is no special concern regarding 
carcinogenic potential 
Tested in vitro and in vivo 18/05/2011 
66
 
Yervoy ipilimumab unique  
entity 5
 
In accordance with ICH S6 (R1) guideline and ICH S1A Guideline on the need for carcinogenicity studies of 
pharmaceuticals (CPMP/ICH/140/95) no studies on genotoxicity and carcinogenicity were conducted, which was 
acceptable. In addition, considering the lack of relevance of the rodent species for ipilimumab, the limited value of short-
term carcinogenicity studies with homologous products (as reflected in the draft reviewed  
13/07/2011 
67
 
Zoely nomegestrol acetate 
/ estradiol unique  entity 6
 No test on combination: single ingredients already tested Tested in vitro and in vivo 27/07/2011 
68
 
Zytiga abiraterone acetate unique  
entity 7
 rat and monkey repeated dose studies,  2-yr rat CARC study, a 6-month CARC study in Tg.rasH2 
mouse model will be performed. Tested in vitro and in vivo
 05/09/2011 
 68 
 
[continue] 
 Name  Active ingredient Cat. Rev. Carcinogenicity Studies 
in vitro Genotox 
studies 
in vivo Genotox 
studies 
Date of 
approval 
1
 
Adempas riociguat orphan 1  2-yr CARC study in rats and mice oral administration Tested in vitro and in vivo 27/03/2014 
2
 
Anoro 
umeclidinium 
bromide / 
vilanterol 
trifenatate 
unique 
entity 0
 
Two 13-week mouse oral studies;  
2-year CARC rat  
2-year CARC mouse inhalation studies. Tested single 
ingredients. 
Tested in vitro and in vivo 08/05/2014 
3
 
BiResp Spiromax 
budesonide / 
formoterol 
fumarate 
dihydrate 
unique 
entity 0
 
The toxicology studies were taken from the FDA 
Pharmacology Reviews (FDA, 2001; FDA 2006) cited unless 
otherwise specified. The doses of drugs and species used in a 
number of the toxicology studies reported were not specified. 
No genotoxicity testing 28/04/2014 
4
 
Brimica Genuair 
aclidinium / 
formoterol 
fumarate 
dihydrate 
unique 
entity 0
 
No CARC studies have been conducted with 
aclidinium/formoterol since both individual active substances 
have been comprehensively investigated. The lack of 
carcinogenicity studies with the proposed combination is 
accepted by the CHMP. 
Tested impurities in vitro only 19/11/2014 
5
 
Budesonide/Form
oterol Teva 
budesonide / 
formoterol 
fumarate 
dihydrate 
unique 
entity 0
 No new toxicity studies have been performed for this MAA; the nonclinical toxicology summary is largely based on the information available for the Symbicort Turbohaler reference product. No original study reports are available. Considering 
this is a hybrid application this approach is acceptable 19/11/2014
 
6
 
Budesonide/Form
oterol Teva 
Pharma B.V. 
budesonide / 
formoterol 
unique 
entity 0
 No new toxicity studies have been performed for this MAA; the nonclinical toxicology summary is largely based on the information available for the Symbicort Turbohaler reference product. No original study reports are available. Considering 
this is a hybrid application this approach is acceptable 19/11/2014
 
7
 
Clopidogrel/Acety
lsalicylic acid 
Teva 
clopidogrel / 
acetylsalicylic acid 
unique 
entity 0
 2-yr CARC study in rats;  
78-weeks in mice on single compound  01/09/2014 
8
 
Cometriq cabozantinib orphan- conditional 
approval 
2 
Carcinogenicity evaluations of XL184 have not been conducted based on the absence of genotoxicity in both in vitro and in 
vivo bioassays, the lack of preneoplastic lesions in chronic repeat-dose toxicity studies in rats and dogs, the lack of 
demonstrated carcinogenic potential in the RTKi product class, and the intended treatment population of subjects with 
advanced, progressive MTC with limited treatment options and a relatively short life expectancy (which is supported by the 
interim overall survival results from the pivotal study XL184-301), in accordance with ICH S1A and ICH S9.  
21/03/2014 
9
 
Daklinza daclatasvir 
dihydrochloride 
unique 
entity 1
 2-yr CARC study in SD rats 
26-week study in Tg-rasH2 transgenic mice  Tested in vitro and in vivo 22/08/2014 
10
 
Deltyba delamanid orphan- conditional 
approval 
2 2-yr CARC study in rats and mice Tested in vitro and in vivo 28/04/2014 
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11
 
Duaklir Genuair aclidinium bromide / formoterol 
fumarate dihydrate 
unique  
entity 0
 
No CARC studies have been conducted with aclidinium/formoterol 
since both individual active substances have been 
comprehensively investigated. The lack of carcinogenicity studies 
with the proposed combination is accepted by the CHMP. 
No genotoxicity testing 19/11/2014 
12
 
DuoResp 
Spiromax 
budesonide / 
formoterol 
fumarate dihydrate 
unique  
entity 1
 
5 studies; + 91 weeks in mice. 
The toxicology studies were taken from the FDA Pharmacology 
Reviews (FDA, 2001; FDA 2006) cited unless otherwise specified. 
The doses of drugs and species used in a number of the toxicology 
studies reported were not specified. 
No genotoxicity testing 28/04/2014 
13
 
Entyvio vedolizumab unique  
entity 0
 
Conventional carcinogenicity risk assessment studies (ie, rodent 
bioassays) have not been conducted with vedolizumab as rodents 
are not pharmacologically responsive to this mAb. This is 
consistent with ICH Guideline S6(R1). Only unconventional in vitro 
Genotoxicity studies were not conducted as vedolizumab 
is a humanized monoclonal antibody and so are not 
required in-line with ICH Guideline S6(R1). 22/05/2014
 
14
 
Envarsus tacrolimus unique  
entity 0
 
The toxicity of tacrolimus has been previously well described in the 
literature. Therefore, no new toxicity studies were conducted by the 
applicant with the prolonged release formulation of tacrolimus, 
which is accepted by the CHMP. 
No genotoxicity testing 18/07/2014 
15
 
Eperzan albiglutide unique  
entity 1
 No CARC studies have been conducted. Because of the emergence of clearing anti-albiglutide antibodies by 14 days in 
rodents, meaningful 2-year studies in rats or mice are not feasible. No genotoxicity testing 21/03/2014
 
16
 
Gazyvaro obinutuzumab orphan 0 
The lack of genotoxicity studies with obinutuzumab is acceptable because antibodies do not have the potential to cross the cell 
membrane.No studies have been performed to establish the carcinogenic potential of obinutuzumab (SmPC, section 5.3). The 
lack of carcinogenicity studies is considered acceptable based ICH S6 guidance. It should be noted that the present application 
concerns obinutuzumab co-treatment with chlorambucil, which is a human carcinogen. 
23/07/2014 
17
 
Granupas 
(previously Para-
aminosalicylic 
acid Lucane) 
para-aminosalicylic 
acid orphan 1 performed previously; literature data reported 
The applicant has suggested that a review of the 
literature identified no general toxicity studies of PAS that 
were relevant to the application. Some studies will be 
performed post-authorization. 
07/04/2014 
18
 
Harvoni sofosbuvir / 
ledipasvir unique  entity 0
 
A 6-month rasH2 transgenic mouse study and a 2-year rat oral 
gavage carcinogenicity study with ledipasvir are being conducted. 
This is acceptable in view of the proposed short term treatment 
duration. The applicant will submit these studies in December 
2015. 
Tested in vitro and in vivo 17/11/2014 
19
 
Hemangiol propranolol  HCl unique  
entity 2
 No carcinogenicity testing The applicant detailed the published genotoxicity data 
with propranolol - known substance 23/04/2014 
20
 
Imbruvica ibrutinib orphan 0 
The carcinogenicity will be tested in a Transgenic (Tg) mouse 
range-finder study (to be submitted by 3Q 2015) followed by a Tg 
ras H2 6 month mouse carcinogenicity study as a non-clinical post 
authorisation measure.  Advance cancer treatment no need for 
testing. 
No genotoxicity testing 21/10/2014 
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21
 
Incruse umeclidinium 
bromide unique  entity 0
 2-yr CARC study in rats and mice  Tested in vitro and in vivo 28/04/2014 
22
 
Izba travoprost unique  
entity 0
 Old data evaluated already for previous formulation Data from literature 20/02/2014 
23
 
Jardiance empagliflozin unique  
entity 0
 2-yr CARC study in rats and mice + additional in vivo in mice Tested in vitro and in vivo 22/05/2014 
24
 
Kolbam 
(previously 
Cholic Acid FGK) 
 
cholic acid 
orphan - 
exception
al 
circumsta
nces 
2 Long-term monitoring of the risk for carcinogenicity is included as 
an element in the Risk Management Plan. Data from literature 04/04/2014 
25
 
Latuda lurasidone unique  
entity 1
 2-yr CARC study in rats and mice  Tested in vitro and in vivo 21/03/2014 
26
 
Laventair umeclidinium 
bromide / vilanterol unique  entity 0
 2-yr CARC study in rats and mice  Tested in vitro and in vivo 08/05/2014 
27
 
Lynparza olaparib orphan 0 
No CARC studies were provided which is acceptable according to 
ICH S9 and in line with the protocol assistance received. Possible 
occurrence of new malignancies due to the pharmacological action 
of olaparib will be closely monitored 
 Tested in vitro and in vivo 16/12/2014 
28
 
Mekinist trametinib unique  
entity 0
 No carcinogenicity testing. In accordance with ICH S9, carcinogenicity studies are not necessary for the approved anti-
cancer indication. Tested in vitro and in vivo 30/06/2014
 
29
 
Mirvaso brimonidine 
tartrate unique  entity 1
 In support of the application, a dermal photo (co)carcinogenicity study in mice and a 2-year dermal carcinogenicity study in rats 
supported by toxicokinetic data have been performed. No genotoxicity testing
 21/02/2014 
30
 
Moventig naloxegol oxalate unique  
entity 0
 2-yr CARC studies in CD1 mice and SD rats.  Tested in vitro and in vivo 08/12/2014 
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31
 
Neuraceq florbetaben (18F) unique  
entity 3
 
Considering the absence of a genotoxic risk for florbetaben HCl 
and the intended clinical use of florbetaben, and according to the 
Guideline on the need of carcinogenicity studies of 
pharmaceuticals (CPMP/ICH/140/95 S1A), no carcinogenicity 
studies are required for florbetaben. 
No genotoxicity testing 20/02/2014 
32
 
Nuwiq simoctocog alfa unique  
entity 0
 Nuwiq is a recombinant B-domain-deleted (BDD) rFVIII human FVIII concentrate that is produced in genetically modified human 
embryonic kidney (HEK) 293F cells. No genotoxicity testing
 24/07/2014 
33
 
Olysio simeprevir unique  
entity 0
 The lack of carcinogenicity studies was justified by the Applicant in line with ICH S1A and based on the proposed treatment duration of 
12 weeks for TMC435. tested in vitro and in vivo
 14/05/2014 
34
 
Plegridy peginterferon beta-
1a unique  entity 2
 Consistent with the ICHS6 Addendum, a weight of evidence approach was taken in the evaluation of the potential 
carcinogenicity risk of BIIB017 for humans.  Tested in vitro only
 18/07/2014 
35
 
Pregabalin Pfizer pregabalin unique  
entity 1
 
Since this application is an informed consent of the Lyrica 
application, the non-clinical data in support of the Pregabalin Pfizer 
application are identical to the up-to-date non-clinical data of the 
Lyrica dossier, which has been assessed and approved 
No genotoxicity testing 10/04/2014 
36
 
Revinty Ellipta fluticasone furoate / vilanterol 
trifenatate 
unique  
entity 0
 
No non-clinical data have been submitted in the Revinty Ellipta 
dossier, since this application is an informed consent of the Relvar 
Ellipta application: the non-clinical data in support of the Revinty 
Ellipta application are identical to the up-to-date non-clinical data of 
the Relvar Ellipta dossier, which have been assessed and 
approved. 
No genotoxicity testing 02/05/2014 
37
 
Rezolsta darunavir / 
cobicistat unique  entity 0
 No non-clinical studies were performed with the combination of darunavir and cobicistat. This was considered acceptable by the 
CHMP. The two active ingredients were previously authorized No genotoxicity testing
 19/11/2014 
38
 
Simbrinza brinzolamide / brimonidine 
tartrate 
unique  
entity 0
 
This application concerns a fixed combination medicinal product 
including both brinzolamide and brimonidine in the same strengths 
as approved for the mono-component products The non-clinical 
assessment of the Simbrinza is mainly based upon the established 
non-clinical profiles of the individual approved active drug 
substances 
No genotoxicity testing 18/07/2014 
39
 
Sirturo bedaquiline 
fumarate 
orphan – 
condition 
approval 
1 On-going study in rats, only. 
 
Due to poor tolerability of bedaquiline in mouse, a carcinogenicity 
study in mouse is not being conducted Tested in vitro and in vivo single substances only
 05/03/2014 
40
 
Sovaldi sofosbuvir unique  
entity 1
 2-yr CARC study in rats and mice. Tested in vitro and in vivo 16/01/2014 
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41
 
Sylvant siltuximab orphan 1 
No carcinogenicity testing. Evidence from studies conducted with 
siltuximab and other IL-6 inhibitors suggest that the potential for 
siltuximab to cause carcinogenicity is low. No genotoxicity testing
 22/05/2014 
42
 
Tecfidera dimethyl fumarate unique  
entity 2
 2-yr CARC study in rats and mice, oral  Standard test battery according to ICHS2A and B 
guidelines 30/01/2014 
43
 
Tivicay dolutegravir unique  
entity 2
 101-104-week study in rats, oral 
88-95-week study in mice, oral Tested in vitro and in vivo 16/01/2014 
44
 
Translarna ataluren orphan – condtion 
approval 
1 26-week CARC study in Tg.rasH2 mice  
24-month CARC study in rats Tested in vitro and in vivo 31/07/2014 
45
 
Triumeq 
abacavir sulfate / 
dolutegravir 
sodium / 
lamivudine 
unique  
entity 0
 The applicant applied for registration of Triumeq film-coated tablets, a fixed dose combination (FDC) product containing dolutegravir, abacavir and lamivudine. No new studies were performed with the combination dolutegravir, abacavir and 
lamivudine UNDER MONITORING 01/09/2014
 
46
 
Trulicity dulaglutide unique  
entity 0
 
The human relevance of thyroid C-cell tumours from the GLP-1 
receptor agonist class is unknown and at this time a potential to 
cause carcinogenicity in man cannot be completely ruled out. The 
findings have been included in SmPC. 
No genotoxicity testing 21/11/2014 
47
 
Ulunar 
Breezhaler 
glycopyrronium 
bromide / 
indacaterol 
maleate 
unique  
entity 0
 
This application is an informed consent of the Ultibro Breezhaler 
application: the non-clinical data in support of the Ulunar 
Breezhaler application are identical to the up-to-date non-clinical 
data of the Ultibro Breezhaler dossier, which have been assessed 
and approved. 
No genotoxicity testing 23/04/2014 
48
 
Vargatef nintedanib unique  
entity 0
 
Vargatef is indicated in combination with docetaxel for the 
treatment of adult patients with locally advanced, metastatic or 
locally recurrent non-small cell lung cancer (NSCLC) of 
adenocarcinoma tumour histology after first-line chemotherapy. 
Genotoxicity studies indicated no mutagenic potential for 
nintedanib.According to the ICH S9 carcinogenicity 
studies are not warranted in the context of the proposed 
indication for ( second line and in combination with 
docetaxel). 
21/11/2014 
49
 
Velphoro 
mixture of 
polynuclear 
iron(III)-
oxyhydroxide, 
sucrose and 
starches 
unique  
entity 0
 2-yr CARC studies in mice  and rats Tested in vitro and in vivo 26/08/2014 
50
 
Vimizim 
recombinant 
human n-
acetylgalactosamin
e-6-sulfatase 
(rhgalns) 
orphan 2 
No carcinogenicity testing. 
The enzymatic activity of elosulfase alfa is restricted to the 
lysosomal compartment where it specifically degrades KS and this 
mode of action does not raise concern of a potential for neoplasm 
induction or tumour promotion 
No genotoxicity studies were performed and the conduct 
of such studies is not considered necessary due to the 
protein structure and the enzymatic activity of the drug 
substance, which is acceptable to the CHMP. 
28/04/2014 
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51
 
Vizamyl flutemetamol (18F) unique  
entity 1
 
Carcinogenicity studies have not been conducted, because 
Flutemetamol (18F) Injection is a diagnostic imaging agent 
intended for infrequent administration with significant intervals 
between treatments 
Tested in vitro and in vivo 22/08/2014 
52
 
Vokanamet canagliflozin / metformin 
hydrochloride 
unique  
entity 1
 2-yr CARC study in rats and mice Tested in vitro and in vivo 23/04/2014 
53
 
Vylaer Spiromax budesonide / formoterol 
fumarate dihydrate 
unique  
entity 0
 
No carcinogenicity testing. 
The nonclinical toxicology summary is largely based on the 
information available for the Symbicort Turbohaler reference 
product. No original study reports are available. Considering this is 
a hybrid application this approach is acceptable. 
No genotoxicity testing 19/11/2014 
54
 
Xigduo 
metformin 
hydrochloride / 
dapagliflozin 
propanediol 
monohydrate 
unique  
entity 1
 No carcinogenicity testing.  The individual toxicities of dapagliflozin and metformin were 
previously established in a comprehensive investigational program No genotoxicity testing
 16/01/2014 
55
 
Xultophy insulin degludec / 
liraglutide unique  entity 0
 
This is a fixed combination of the two approved active substances 
insulin degludec and liraglutide. The applicant has submitted 
summaries on the pharmacology, pharmacokinetics and toxicology 
of the individual components. No data reported 
No genotoxicity testing 18/09/2014 
56
 
Zydelig idelalisib unique  
entity 0
 
No CARC studies with idelalisib have been conducted. 
Carcinogenicity studies are in general not required to support 
marketing for therapeutics intended to treat patients with advanced 
cancer.  
Tested in vitro and in vivo 18/09/2014 
57
 
Busulfan 
Fresenius Kabi busulfan generic 0 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. 22/09/2014
 
58
 
Ebilfumin oseltamivir generic 1 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product.  22/05/2014
 
59
 
Levetiracetam 
Hospira levetiracetam generic 1 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justified why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC were in line with the SmPC of the reference 
product.  
08/01/2014 
60
 
Tadalafil Mylan tadalafil generic 0 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product.  21/11/2014
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61
 
Zoledronic Acid 
Accord zoledronic acid monohydrate generic 0 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. 
The impurity profile has been discussed and was considered acceptable. 
16/01/2014 
62
 
Zoledronic acid 
Teva Generics zoledronic acid monohydrate generic 2 
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date 
and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, 
pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. 
The impurity profile has been discussed and was considered acceptable. 
27/03/2014 
63
 
Abasaglar 
(previously 
Abasria) insulin glargine
 biosimilar 1 
In line with current guidelines on the development of similar 
biological medicinal products, no carcinogenicity studies have been 
performed; more data were provided to confirm biosimilarity 
In line with current guidelines on the development of 
similar biological medicinal products, no genotoxicity 
studies have been performed 09/09/2014
 
64
 
Accofil filgrastim biosimilar 0 
According to the Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor 
(EMEA/CHMP/BMWP/31329/2005), safety pharmacology, reproduction toxicology, mutagenicity and carcinogenicity studies are 
not routine requirements for non-clinical testing of similar biological medicinal products containing recombinant G-CSF as active 
substance. 
18/09/2014 
65
 
Bemfola follitropin alfa biosimilar 1 
No carcinogenicity testing. 
In accordance with both the ICH S6 guideline on the development 
of biotechnology-derived pharmaceuticals 
Genotoxicity studies are not required for a biosimilar 
medicinal product. This is in accordance with both the 
ICH S6 guideline and the CHMPguideline on the 
development of biosimilar products 
27/03/2014 
66
 
Rivastigmine 3M 
Health Care Ltd rivastigmine generic - The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. withdrawn 
67
 
Masican masitinib orphan - 2-yr CARC study in rats and mice Tested in vitro and in vivo refused 
68
 
Masiviera masitinib orphan - 2-yr CARC study  in rats and mice Tested in vitro and in vivo refused 
69
 
Nerventra laquinimod unique 
entity -
 104-week study in rats 
26-week in p53 mice Tested in vitro and in vivo refused 
70
 
Reasanz serelaxin unique 
entity -
 No carcinogenicity testing. Relaxin (H2) is a naturally occurring peptide hormone 
(molecular weight of 5963 Daltons) No genotoxicity testing
 refused 
Legend 
Rev.: Revision number 
Cat.: Category of medicines as: unique entity, orphan, generic, biosimilar etc.  
The information reported in the table was retrieved from EMA website (http://www.ema.europa.eu/ema/) and EPARs publicly available documents. 
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 Name 
Active 
ingredient 
Cat. Rev. Carcinogenicity Studies 
in vitro Genotox 
studies 
in vivo Genotox 
studies 
Date of 
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1
 
Activyl indoxacarb unique 
entity 0
 Tested  Tested in vitro and in vivo 18/02/2011 
2
 
Bluevac BTV8 bluetongue virus inactivated, 
serotype 8 
Accelerat
ed 
procedure
– 
condition 
approval 
0 No carcinogenicity testing  - vaccine No genotoxicity testing 14/04/2011 
3
 
CaniLeish Leishmania infantum excreted 
secreted proteins 
unique 
entity 0
 No carcinogenicity testing  - vaccine No genotoxicity testing 14/03/2011 
4
 
Certifect fipronil /amitraz 
/(S)-methoprene unique entity 0
 The omission of reproductive, genotoxicity and carcinogenicity studies is justified by the demonstration of the non-interaction and 
the use of well-established substances. No genotoxicity testing
 06/05/2011 
5
 
Cimalgex cimicoxib unique 
entity 0
 
No carcinogenicity studies were performed. Cimicoxib is not 
genotoxic, no structural alerts have been identified, and there was 
no signal indicating carcinogenic potential in the repeated dose 
toxicity studies.  
Tested in vitro and in vivo 18/02/2011 
6
 
Comfortis spinosad unique 
entity 0
 18- and 24-moths studies in mice; A combined chronic 
toxicity/neurotoxicity/oncogenicity study was conducted in rats. Tested in vitro and in vivo 11/02/2011 
7
 
Emdocam meloxicam generic 0 
Given that bioequivalence of the test and reference products was 
accepted, the Committee agreed that no data in respect of 
pharmacology or toxicology are required. No genotoxicity testing
 18/08/2011 
8
 
Hiprabovis IBR 
Marker Live 
live gE- tk- double-
gene-deleted 
bovine herpes 
virus type 1, strain 
unique 
entity 0
 
No need for carcinogenicity testing. 
The active substance of Hiprabovis IBR Marker Live is a live 
double-gene deleted (deleted glycoprotein E (gE-) and deleted 
thymidine kinase (tk-/+) Bovine Herpes Virus type 1, strain 
No genotoxicity testing 27/01/2011 
9
 
Inflacam meloxicam generic 0 
As essential similarity to the reference product was confirmed, the 
results of toxicological and pharmacological tests and clinical trials 
were not required in accordance with Article 13 of Directive 
2001/82/EC, as amended. 
No genotoxicity testing 09/12/2011 
10
 
Melosus meloxicam generic 0 
The applicant has claimed bioequivalence with Metacam 1.5mg/ml 
oral solution and that data in support of the pharmacology and 
toxicology of meloxicam are not required No genotoxicity testing
 21/02/2011 
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11
 
MS-H Vaccine Mycoplasma synoviae strain 
MS-H 
unique 
entity 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 14/06/2011 
12
 
Nobivac Myxo-
RHD 
live myxoma-
vectoredrabbit-
haemorrhagic-
disease virus strain 
009 
unique 
entity 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 07/09/2011 
13
 
Panacur AquaSol fenbendazole unique 
entity 0
 
Fenbendazole, the active substance contained in Panacur 
AquaSol, is a well-established substance that has been widely and 
safely used for more than 30 years. Therefore, the applicant refers 
to published, valid safety assessment of fenbendazole including 
the CVMP MRL summary report EMEA/MRL/193/97-FINAL. 
No genotoxicity testing 09/12/2011 
14
 
Procox emodepside/ 
toltrazuril unique entity 0
  Tested for carcinogenicity - combination Tested in vitro and in vivo 20/04/2011 
15
 
Proteq West Nile vCP2017 virus unique 
entity 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 05/08/2011 
16
 
Purevax Rabies vCP65 virus unique 
entity 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 18/02/2011 
17
 
Recocam meloxicam generic 0 No carcinogenicity testing No genotoxicity testing 13/09/2011 
18
 
Recuvyra Fentanyl unique 
entity 0
 No carcinogenicity testing Tested in vitro and in vivo 06/10/2011 
19
 
TruScient dibotermin alfa unique 
entity 0
 
In vitro studies to assess the potential effects of dibotermin alfa on 
tumour cell growth using various tumour cell lines and primary 
tumour isolates. Additionally, studies in mice to assess whether 
surgical implantation of dibotermin alfa/ACS augmented the growth 
of subcutaneously injected human tumour cell lines (xenografts) 
suggest minimal potential for dibotermin alfa to stimulate tumour 
cell growth.  
Tested in vitro (AMES) only withdrawn 
20
 
Veraflox pradofloxacin unique 
entity 0
 2-yr CARC study in rats and mice Tested in vitro and in vivo 12/04/2011 
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21
 
Zulvac 1 Bovis inactivated bluetongue virus, 
serotype 1 
accelerated 
procedure 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 05/08/2011 
22
 
Zulvac 1  
Ovis 
inactivated 
bluetongue virus, 
serotype-1 
accelerated 
procedure 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 05/08/2011 
23
 
Zulvac 1+8 Ovis 
inactivated 
bluetongue virus, 
serotype 1/ 
inactivated 
bluetongue virus, 
serotype 8 
Condition 
approval 0
 Vaccine – No carcinogenicity testing No genotoxicity testing 14/03/2011 
24
 
Zuprevo tildipirosin unique 
entity 0
 
No carcinogenicity testing 
Due to the absence of a chemical relationship to known 
carcinogens, the negative results of genotoxicity assays and the 
lack of carcinogenic potential of other macrolide antibiotics, it is 
assumed that tildipirosin is devoid of a carcinogenic risk. 
 Tested in vitro and in vivo  06/05/2011 
 
Legend 
Rev.: Revision number 
Cat.: Category of medicines as: unique entity, orphan, generic, biosimilar etc. 
The information reported in the table was retrieved from EMA website (http://www.ema.europa.eu/ema/) and EPARs publicly available documents. 
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1
 
Bravecto fluralaner unique 
entity 0
 
Studies on fluralaner for carcinogenic potential were not submitted. 
This is justified by the negative results in all mutagenicity assays 
and the absence of pre-neoplastic lesions in repeated dose toxicity 
studies 
Tested in vitro and in vivo 11/02/2014 
2
 
Equisolon prednisolone unique 
entity 0
 
Toxicology data for prednisolone have previously been assessed by the CVMP and the toxicological profile is presented in the 
European Public MRL Assessment Report (EPMAR) of prednisolone (EMEA/MRL/629/99-FINAL, July 1999). No new data on 
prednisolone toxicity were provided in this application. The applicant requested classification for minor use minor species 
(MUMS)/limited market status this product by the CVMP.  
12/03/2014 
3
 
Eryseng 
Erysipelothrix 
rhusiopathiae, 
strain R32E11 
(inactivated) 
unique 
entity 0
 Vaccine similar to a combined one for which several studies were 
performed – no carcinogenicity test needed No genotoxicity testing 04/07/2014 
4
 
Eryseng Parvo 
porcine parvovirus, 
strain NADL-2 and 
Erysipelothrix 
rhusiopathiae, 
strain R32E11 
(inactivated) 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 08/07/2014 
5
 
Fungitraxx itraconazole unique 
entity 0
 As itraconazole was shown to be devoid of mutagenic/genotoxic potential in a suitable battery of tests, the absence of any further carcinogenicity data/studies is acceptable. In addition the molecule has no structural alerts related to any potential 
carcinogenic risk. Itraconazole should therefore be considered as devoid of mutagenic/genotoxic and carcinogenic potential. 12/03/2014
 
6
 
NexGard afoxolaner unique 
entity 0
 Similar product authorized in 2015 combination – no testing Tested in vitro and in vivo 11/02/2014 
7
 
Nobilis IB Primo 
QX 
live avian 
infectious 
bronchitis virus, 
strain D388 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 04/09/2014 
8
 
Osurnia 
terbinafine 
/florfenicol 
/betamethasone 
acetate 
unique 
entity 0
 3 active substances combined data reported in previous MRL studies reports no genotoxic no carcinogenic potential. No further 
testing needed 31/07/2014 
9
 
Porcilis PCV M 
Hyo 
porcine circovirus 
type 2 ORF2 
subunit antigen, 
Mycoplasma 
hyopneumoniae 
strain ATCC 25934 
(inactivated) 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 07/11/2014 
10
 
Vectra Felis pyriproxyfen / 
dinotefuran unique entity 0
 Data already presented for a previous product (VECTRA 3D) 06/06/2014 
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11
 
Versican Plus 
DHPPi Canine distemper adenovrus… unique entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 04/07/2014 
12
 
Versican Plus 
DHPPi/L4 Canine distemper adenovrus… unique entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 07/05/2014 
13
 
Versican Plus 
DHPPi/L4R Canine distemper adenovrus… unique entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 07/05/2014 
14
 
Versican Plus L4 
Leptospira 
interrogans 
serogroup 
Australis serovar 
Bratislava, 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 31/07/2014 
15
 
Versican Plus Pi 
Canine 
parainfluenza type-
2 virus, strain 
CPiV-2 Bio 15 (live 
attenuated) 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 04/07/2014 
16
 
Versican Plus 
Pi/L4 
Canine 
parainfluenza type 
2 virus 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 31/07/2014 
17
 
Versican Plus 
Pi/L4R 
Canine 
parainfluenza virus 
(live attenuated), 
canine 
leptospirosis and 
rabies (inactivated) 
vaccine 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 31/07/2014 
18
 
Bovela 
modified live 
bovine viral 
diarrhoea virus 
type 1, 
unique 
entity 0
 Vaccine  - No carcinogenicity testing No genotoxicity testing 22/12/2014 
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 Annex IV.  Plant protection products list of authorized substances in 2011 and 2014  
 Substance Category Submission  Carcinogenicity Studies  in vitro Genotox 
studies 
 in vivo Genotox 
studies 
Studies 
requested 
upon 
submission 
Date of 
approval 
1
 
1-Decanol
 
Plant 
growth 
regulator
 
A4
 
no
 
Waived: is a natural product found in 
environment and body so no need to test 
carcinogenicity; similar conclusion from US 
EPA , it is used as plant growth regulators on 
tobacco so not for human consumption and 
operators exposed for short periods
 
yes
 
Ames, MLA, HPRT, 
COMET, MN
 
yes
 
MN in mouse bone 
marrow
 
 01/06/2011 
2
 
6-
Benzyladenine
 
Plant 
growth 
regulator
 
A4
 
yes
 
Partially waived: one study only in rats with 
limited info;  further studies have been 
waived because not needed
 
yes
 
6 studies: Ames, UDS, CA, 
3 MLA studies
 
yes
 
MN in vivo
  
01/06/2011 
3
 
Aluminium 
sulphate
 
Bactericide
 
A4
 
no
 
Data from literature
 
yes
 
Data from literature
 
yes
 
Data from literature
  
01/06/2011 
4
 
Azadirachtin
 
Insecticide
 
A4
 
no
 
No reliable study submitted
 
yes
 
Data from literature
 
yes
 
Studies performed  
with extracts not all 
of them;
 
Data GAPS, 
though already in 
annex 1 as 
insecticide now 
as acaracide for 
ornamentals 
plants and 
greenhouse
 
01/06/2011 
5
 
Bispyribac
 
Herbicide
 
C
 
yes
 
2-yr CARC study in rats and in  mice;
 52-week study in dog 
yes
 
Reverse mutation in Ames 
test, forward mutations in 
V79 cells, of chromosomal 
aberrations in Chinese 
hamster ovary cells, and of 
DNA damage (UDS in rat 
hepatocytes).
 
yes
 
MN in vivo
  
01/08/2011 
6
 
Bromadiolone
 
Rodenticide
 
A4
 
no
 
waived as: study is not feasible, 
anticoagulant similar to warfarin extremely 
toxic
 
yes
 
Ames, CA, MLA
 
yes
 
MN in vivo mouse
  
01/06/2011 
7
 
Bromuconazole
 
Fungicide
 
A3
 
yes
 
2-yr  CARC study in rats and mice
 
yes
 
Ames, 2 CA, 2 gene 
mutation assays (MLA, and 
V79), UDS ex vivo
 
yes
 
2 studies: MN and 
UDS
 
Some tests 
repeated with 
metabolite and 
impurities
 
01/02/2011 
8
 
Bupirimate
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats and mice; 80-week 
study in mice; 105-week in dogs
 
yes
 
Ames, CA,
 
yes
 
MN, DML
  
01/06/2011 
9
 
Buprofezin
 
Insecticide
 
A3
 
yes
 
2-yr CARC study in rats and mice; 105- week 
study in dogs
 
yes
 
Ames (2 exp. one study 
insufficient) , UDS, MLA, 
CA, Rec assay(I)
 
yes
 
MN (insufficient)
 
Ames test 
repeated with 
parent and 
metabolites
 
01/02/2011 
10
 
Carbetamide
 
Herbicide
 
A3
 
yes
 
combined chronic/CARC in rats, 2-yr study in 
mice; 52-week in dogs
 
yes
 
Several old studies with no 
reliable data or not following 
TG
 
yes
 
UDS in rat liver and 
MN in BM cells, 
revised
 
Category 3 R40
 
01/06/2011 
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in vivo 
Genotox 
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Date of 
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11
 
Carboxin
 
Fungicide
 
A3
 
yes
 
combined chronic/CARC study in rats;  
19-month CARC study in mice
 
yes
 
Ames, CA, UDS, HGPRT
 
yes
 
2 CA studies
 
in vivo UDS, in 
vitro UDS
 
01/06/2011 
12
 
Clethodim
 
Herbicide
 
A3
 
yes
 
2-yr CARC study in rats
 
yes
 
Ames, CA, MLA with 
different metabolites
 
yes
 
MN in mice
 
No original DAR; 
experiments 
performed with 
clethodim sulfone 
and clethodim 
oxazole
 
01/06/2011 
13
 
Cycloxydim
 
Herbicde
 
A3
 
no
 
Only historical data: 18-
monthstudy,drinking, in rats; 2-yr CARC 
study in  rats and in mice
 
no
 
Ames, MLA, CA, UDS
 
no
 
MN and CA
  
01/06/2011 
14
 
Cyproconazole
 
Fungicide
 
A3
 
yes
 
Revised studies in rats and mice; added 
few more metabolic studies
 
yes
 
Ames , CA (3), HGPRT in 
v79cells, mitotic non-Dis-
junct.in yeast, UDS, CTA 
in SHE
 
yes
 
MN, CA, DML
 
Change of cat from 
Cat 3 to Cat 2
 
01/06/2011 
15
 
Dazomet
 
Nematicide, 
Fungicide, 
Herbicide, 
Soil 
treatment
 
A3
 
yes
 
2-yr combined chronic/CARC in rats; 78-
week combined chronic/CARC in mice; 2-yr 
chronic study in rats
 
yes
 
Ames, REC, MLA, HPRT, 
CA-SHE, CA lymph + CTA 
in Balb cells
 
yes
 
UDS, MN bone 
marrow, CH 
spermatogonia
 
Asked for 
measuring [conc] 
of  metabolites for 
exposure limits
 
01/06/2011 
16
 
Diclofop
 
Herbicide
 
A3
 
yes
 
one combined chronic/CARC  and 2-yr 
CARC study in rats; 2-yr CARC study in 
mice
 
yes
 
Ames, CA, HGPRT, UDS
 
yes
 
CA in CHO, CA 
in BM
 
Asked for further 
discussion
 
01/06/2011 
17
 
Diethofencarb
 
Fungicide
 
A3
 
yes
 
3 combined chronic/CARC in rats (3 
batches); two 2-yr studies in mice; 
mechanistic study in rat follicle tumour 
formation.  
Thyroid tumour in rats due to secondary 
damage to the hormone pituitary axis
 
yes
 
Ames, V79 conversion, CA 
(low sensitivity) , SCE, 
UDS (not acceptable)
 
yes
 
CA
 
UDS in vivo
 
01/06/2011 
18
 
Dithianon
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats; 80-week CARC 
study  in mice, 7-d and  28-d oral female 
rats
 
yes
 
Ames, MLA (2), CA, UDS 
(indicative only short 
exposure)
 
yes
 
CA and MN
 
Re-evaluation of 2-
yr study in rats; 
mechanistic 
studies; in vivo : 
MN, Comet, UDS. 
COMET assay 
was considered as 
indicative because 
not fully validated
 
01/06/2011 
19
 
Dodine
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats; 18-month in mice
 
yes
 
Ames (2 batches), 
HGPRT, CA
 
yes
 
2 MN studies
  
01/06/2011 
20
 
Etridiazole
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats; 18-month in mice; 
plus historical data and older studies
 
yes
 
Ames, CA, SCE (2), MLA
 
yes
 
MN, CA, UDS
  
01/06/2011 
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21
 
Fenazaquin
 
Acaricide
 
A3
 
yes
 
2-yr combined chronic/CARC study in 
rats; 18-month in S. hamster
 
yes
 
Ames, CA, MLA, UDS
 
yes
 
MN, liver rat 
DNA repair, in 
vivo SCE in BM 
cells
 
 in vivo MN with 
appropriate staining 
procedure FISH, and in 
vitro MLA and CA for 
the metabolites
 
01/06/2011 
22
 
Fenbuconazole
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats; 18-month  
CARC study in mice
 
yes
 
Not specified
 
yes
 
Not specified
 
 
 
01/05/2011 
23
 
Fenoxycarb
 
Insecticide
 
A3
 
yes
 
Combined chronic/CARC study in 
rats; 78-week study in albino mice; 
80-week study in CD-1 mice; plus 
several  mechanistic studies in rats 
and mice
 
yes
 
Ames, yeast REC, HPRT,CA 
(3)
 
yes
 
MN (2)
 
performed re-
evaluation of 2 year 
CARC study in rats; 
mechanistic studies 
 
01/06/2011 
24
 
Fluometuron
 
Herbicide
 
A3
 
yes
 
52-week chronic study in rats, 
 2-yr CARC study diet in rats, 2-yr 
CARC study in mice
 
yes
 
Ames (2), MLA, CA,DNA 
repair test (3) Clastogenic
 
yes
 
nucleus anomaly 
in BM, MN, 
negative in vivo
 
explanations on 
impurities; re-
evaluation of CARC 
data in mice was not 
accepted
 
01/06/2011 
25
 
Flurochloridone
 
Herbicide
 
A3
 
yes
 
Not specified in the addendum
 
yes
 
Ames (3) + 1new, MLA (2), 
CA, SCE, CTA in Balb cells, 
DNA repair and UDS
 
yes
 
CA in bone 
marrow cells
 
 Additional data for 
impurities (toluene) 
Ames test, acute 
toxicity
 
01/06/2011 
26
 
Flutriafol
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats and in mice; 
 
yes
 
Ames, MLA, CA
 
yes
 
CA, MN, UDS 
and germ cells,  
DML
 
3 more in vitro 
genotoxicity studies 
with new batch with 
impurities in line with 
EC guidance on 
technical equivalences, 
based on results 
perhaps further studies 
could be requested
 
01/06/2011 
27
 
Haloxyfop-P 
(Haloxyfop-R)
 
Herbicide
 
A3
 
yes
 
2-yr CARC study in rats and in mice;
 plus QSAR data 
yes
 
Ames (3), HGPRT, UDS (2), 
CA (3), in the first submission 
plus QSAR data
 
yes
 
MN
 
Asked for metabolites 
relevance
 
01/01/2011 
28
 
Hexythiazox
 
Acaricide, 
Insecticide
 
A3
 
yes
 
2-yr combined chronic/CARC feeding 
in rats, 2-yr CARC study, feeding in 
mice
 
yes
 
Ames, yeast REC, HPRT in 
v79,CA in CHO (2), rec in B. 
subtilis, UDS
 
yes
 
CA, MN (2)
 
Ames test and in vitro 
MLA and CA and in 
vivo MN genotox,  
 
01/06/2011 
29
 
Hymexazol
 
Fungicide
 
A3
 
yes
 
2-yr combined chronic/CARC rats; 
91-week CARC study in mice
 
yes
 
Ames (2), CA, MLA, genmutat 
in v79, UDS in HeLa cells
 
yes
 
MN, sex 
recessive 
Drosophyla,
 
in vitro CA and in vivo 
MN or CA
 
01/06/2011 
30
 
Indolylbutyric 
acid
 
Plant growth 
regulator
 
A4
 
no
 
Waived also in the first submission 
because use for ornamental plants
 
yes
 
Ames (2), HGPRT,CA
 
yes
 
MN
 
ornamental plants, no 
exposure for operators, 
fastly secreted >85% in 
24hrs in rats, no 
histopathol changes  in 
90-days, 1-generation 
study in rats, no Derek 
alerts; 1 Ames test and 
in vivo MN performed
 
01/06/2011 
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Isoxaben
 
Herbicide
 
A3
 
yes
 
1-yr chronic study rats; 2-yr 
combined study in rats, 2-yr 
combined study in mice, 1-yr study in 
dog
 
yes
 
Ames (2), UDS, CA, B. subtilis 
Rec, MLA
 
yes
 
CA,MN (3), DML
 
New data genotox 
were presented for 
metabolites; pec grow 
on metabolite
 
01/06/2011 
32
 
Lime sulphur 
(calcium 
polysulphid)
 
Fungicide, 
Insecticide, 
Acaricide
 
A4
 
no
 
No data presented because no 
references are on its possible 
carcinogenicity effect
 
yes
 
Ames, CA, MLA (in 
submission 2008)
 
yes
 
MN
 
No further test on carc  
or chronic toxicity is 
required but, a UDS in 
vivo
 
01/06/2011 
33
 
Metaldehyde
 
Molluscicide
 
A3
 
yes
 
2-yr combined chronic/CARC in rats; 
2-yr CARC study in rats (limited 
validity), 78-week CARC in mice
 
yes
 
Ames, CA, MLA, DML in  
E.coli
 
yes
 
MN
  
01/06/2011 
34
 
Metosulam
 
Herbicide
 
A3
 
yes
 
2-yr chronic/CARC in rats; 18-month 
chronic/CARC in mice; plus 
exploratory studies on kidney tumour
 
yes
 
Ames (2), gene mutation (2), 
CA (2), UDS
 
yes
 
MN, and then 
new COMET
 
Ames test; cat CARC 3 
R40 no genotoxic 
mechanism
 
01/05/2011 
35
 
Myclobutanil
 
Fungicide
 
A3
 
yes
 
2-yr chronic/CARC rats; 2-yr  CARC 
study in mice, 18-month study  
repeated in female mice
 
yes
 
Ames, HGPRT, CA, UDS
 
yes
 
CA (2) , DML
 
Literature
 
01/06/2011 
36
 
Napropamide
 
Herbicide
 
A3
 
yes
 
2-yr combined chronic/CARC studies 
in rats; 18-month CARC in mice
 
yes
 
Ames 2, MLA, HPRT,HPRT in 
v79, CA 2, DNA damage  (2), 
Rec assay, UDS
 
yes
 
MN (2), UDS
 
Additional data on the 
metabolite NOPA: 
Ames, MLA, CA in 
vitro, CA in vivo
 
01/01/2011 
37
 
Oryzalin
 
Herbicide
 
A3
 
yes
 
12-month study and  two 2-yr CARC 
studies in rats; 12-month and two  
2-yr CARC studies in mice
 
yes
 
Ames, MLA, CA and UDS (not 
accepted),
 
yes
 
CA (3, but one 
not accepted), 
DML (2, but 
supportive only)
 
Further data and 
discussion for 
carcinogenicity in mice 
and genotox in vivo CA 
one more Ames sudy 
was performed and 
data discussed; after 
submitting additional 
discussion , more info 
of non-relevance of 
thyroid follicular tumour 
in rats was asked; Xn 
harmful and R40
 
01/06/2011 
38
 
Paclobutrazol
 
Plant growth 
regulator
 
A3
 
yes
 
2-yr CARC studies in rats and mice
 
yes
 
Ames, MLA, CA,
 
yes
 
2 CA, 2 MN in 
mice, UDS, DML
 
only discussion and 
historical data
 
01/06/2011 
39
 
Pencycuron
 
Fungicide
 
A3
 
yes
 
2-yr CARC study in rats; 2-yr CARC 
study in mice
 
yes
 
Ames (3 studies, one 
performed for resubmission), 
rec assays (4), yeast mit-rec 
(2), CA (2), UDS, HGPRT,
 
yes
 
2 MN, 2 DML
 
no further data 
requested; Ames 
performed, re-
evaluation of carc 
study in rats;
 
01/06/2011 
40
 
Profoxydim
 
Herbicide
 
C
  
in the list of new database for 
genotoxicity profiling launched in July 
2014
 
no DAR available
  
01/08/2011 
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Pyridaben
 
Acaricide, 
Insecticide
 
A3
 
yes
 
2-yr CARC study in rats; 18-month 
CARC study  in mice
 
yes
 
Ames, HGPRT, CA, DNA 
repair
 
yes
 
MN
 
Further discussion on 
CARC data in rats was 
presented for resubmission
 
01/05/2011 
42
 
Quinmerac
 
Herbicide
 
A3
 
yes
 
12-month in rats; 2-yr combined 
chronic/CARC study in rats; 
 78-week CARC study in mice;  Plus supplementary 78-weeks in 
mice
 
yes
 
Ames (2), CA, HPRT, UDS, 
MLA
 
yes
 
MN
 
Asked for more data 
especially in regard of 
metabolites; Ames test, 
MLA with parent and MLA 
with metabolites MN in vivo 
were additionally performed 
for submission
 
01/05/2011 
43
 
Sintofen 
 (aka Cintofen) 
Plant growth 
regulator
 
A3
 
yes
 
52-weeks dietary rats interim, 
 2-yr combined chronic/CARC study 
in rats; 
 78-week CARC study in mice 
yes
 
Ames (3, one performed in 
2008),HPRT in v79 cells, CA 
in CHO,UDS
 
yes
 
MN in BM 
cells,
 
No further studies 
requested presented 
additional information on 
CARC and historical data
 
01/06/2011 
44
 
tau-
 Fluvalinate 
Insecticide 
 
A3
 
yes
 
2-yr combined chronic/CARC study 
in rats and mice
 
yes
 
Ames, MLA, CA, SCE (2), 
UDS
 
yes
 
CA
 
Compliance of the batches 
tested in the mammalian 
toxicology data package to 
the proposed specification 
cannot be demonstrated, in 
particular for the 
genotoxicity and 
carcinogenicity studies
 
01/06/2011 
45
 
Tebufenozide
 
Insectide 
 
A3
 
yes
 
2-yr combined chronic/CARC study 
in rats; 18-month study CARC in 
mice
 
yes
 
Ames, CA, HGPRT, UDS
 
yes
 
CA
 
 
 
01/06/2011 
46
 
Triazoxide
 
Insectide
 
A3
 
yes
 
2-yrr CARC study rats; 21-month 
study in mice
 
yes
 
Ames, polA assay, HGPRT, 
CA, UDS
 
yes
 
DML, CA (2), 
MN
 
Re-evaluation of cancer 
study 2-yr rats for dark 
spleen colouring; LOAEL 
and ADI reconsidered in 
May 2010
 
01/10/2011 
47
 
Triflumuron
 
Insecticide
 
A3
 
yes
 
2-yr CARC study rats and  in mice
 
yes
 
Ames (2), HGPRT, UDS,SCE, 
CA
 
yes
 
MN
 
 
 
01/04/2011 
48
 
Zinc 
phosphide
 
Rodenticide
 
A4
 
yes
 
Performed only in rats combined 
chronic/CARC;  
 Two 2-yr  CARC studies in rats 
yes
 
No data with zinc phosphide; 
only with phosphine PH3: 
Ames (4), CA, HGPRT
 
yes
 
CA, MN, UDS, 
DML, SCE (2)
 
Tested only with phosphine 
no other test required
 
01/05/2011 
 
  
 85 
 
[continue] 
 Substance Category Submission  Carcinogenicity Studies  in vitro Genotox studies  in vivo Genotox studies 
Date of 
approval 
1
 
1,4-Dimethyl-
naphthalene
 
Plant 
growth 
regulator
 
C
 
yes
 
2-yr combined chronic/CARC in rats;  2-
yr combined chronic/CARC study in 
mice
 
yes
 
2 AMES studies, MLA, UDS
 
yes
 
MN in mouse MPEs and UDS in rat 
liver
 
01/07/2014 
2
 
Acequinocyl
 
Acaricide
 
C
 
yes
 
2-yr combined chronic/CARC study in 
rats; 80-week CARC study mouse
 
yes
 
AMES, CA in CHL cells
 MLA - on metabolites also 
yes
 
MN  - on metabolites also
 
01/09/2014 
3
 
Amisulbrom
 
Fungicide
 
C
 
yes
 
2-yr combined chronic/CARC study in 
rats;
 78-week CARC study in mice 
yes
 
AMES, MLA, CA in human 
lymphocytes studies
 
yes
 
MN in mouse BM oral, UDS, MN in liver 
rats oral, Rat liver COMET, Mouse liver 
COMET, Rat stomach/forestomach 
COMET, MN in mouse BM by injection
 
01/07/2014 
4
 
Ascorbic acid
 
Fungicide
 
C
 
no
  
no
 
Not necessary
 Data from literature reported only 
no
 
GRAS product =generally recognized 
as safe. Essential factor in physiology 
of plants and animal, evaluated as safe 
by cosmetic ingredient review panel 
2005 (CIR)
 
01/07/2014 
5
 
Aureobasidiu
m pullulans
 (strains DSM 
14940 and 
DSM 14941)
 
Fungicide, 
Bactericide
 
C
 
no
 
Waived as it is a microorganism and 
pathogenicity/infectivity studies by oral 
or inhalation or subcutaneous 
demonstrate that the microorganism 
does not survive at condition prevailing 
in mammalian cells (temp, pH), short 
term toxicity study not necessary as 
well as CARC study
 
no
 
waived as: in vitro standard test 
are not appropriate to test 
genotoxicity potential of fungal 
cells
 
yes
 
in vivo micronucleus on erythrocytes 
using dry granulate cells of 
Aureobasidium
 
01/02/2014 
6
 
Bacillus 
pumilus QST 
2808
 
Fungicide
 
C
 
no
 
Waived as it is a microorganism only 
tier I test performed
 
no
  
no
 
No infective species which are not able 
to enter mammalian cells. Do not 
exhibit mutagenic effect. (OECD 
guidance no 43, 2008) existing TG are 
not applicable to microbial products) 
genotoxicity is not necessary
 
01/09/2014 
7
 
Benalaxyl-M
 
Fungicide
 
C
 
yes
 
Historical data performed as combined 
chronic/CARC study in rats and one  
2-yr CARC study in mice, plus 
pathology peer review
 
yes
 
2 AMES studies, yeast gene 
mutation (2), MLA, gene mutation 
in V79 cells CA in CHO cells, CA in 
human cells
 
yes
 
MN in vivo in BM cells
 
01/05/2014 
8
 
Chitosan 
hydrochloride
 
 C  
no DAR available
 
01/07/2014 
9
 
Chlorantranilip
role
 
Insecticide
 
C
 
yes
 
combined chronic CARC 2-yrs-study in 
rats; 18-month CARC study in mice
 
yes
 
2 AMES studies, 2 CA in human 
lymphocytes, HGPRT in CHO cells 
and metabolites
 
yes
 
MN in vivo in mouse BM
 
01/05/2014 
10
 
Disodium 
phosphonate
 
Fungicide
 
C
 
yes
 
4 studies: two studies in rats: one 
combined chronic/CARC study in rats; 
one CARC study in rats; one 2-yr 
CARC study in dog, one in mice; all 
performed in 1981.
 
yes
 
AMES, CA in V79 cells studies
 
yes
 
MN in vivo in mouse BM
 
01/02/2014 
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Emamectin
 
Insecticide C 
yes
 
104-week combined chronic/CARC 
study in rats; 
 79-week CARC study in mice; 13-
week study in mice for range-finding 
study, 
 semi chronic studies: 13-week in rats;  52-week in rats; 14-week in dogs; 
52–week- in dogs.
 
yes
 
AMES, CA in CHO cells,  HPRT 
in V79 cells, alkaline/elution in 
rat hepatocytes
 
yes
 
CA in mouse BM cells
 
01/05/2014 
12
 
Equisetum
 arvense L. 
  C 
no
 
Waived as a plant extract, no 
assessment performed
 
no
  
no
 
The available data are insufficient both 
qualitatively and quantitatively, and are 
not specifically relevant for Equisetum 
to allow a specific assessment to be 
performed.
 
01/07/2014 
13
 
Flubendiamide
 
Insecticide C  
no DAR available
 
01/09/2014
 
14
 
Fluopyram
 
Fungicide C 
yes
 
104-week combined chronic/ 
CARC in rats;  78-week CARC 
study in mice
 
yes
 
Studies: 2 Ames, HPRT and CA 
in V79 cells
 
yes
 
MN study in BM cells
 
01/02/2014 
15
 
Ipconazole
 
  C 
yes
 
104- week combined 
chronic/CARC study in rats;  78-
week CARC study in mice
 
yes
 
AMES, Bacterial DNA repair, 
CA, HGPRT in CHO cells 
studies
 
yes
 
MN study in BM cells
 
01/09/2014 
16
 
Orange oil 
 (D-limonene) 
Insecticide C 
yes
 
2-yr bioassay reported from NTP 
studies in rats and mice
 
yes
 
5 AMES studies, 2 MLA studies, 
CA, SCE
 
yes
 
Mammalian Spot test, transgenic 
BigBlue mouse induction of Lacz mut, 
COMET assay in kidney,
 
01/05/2014 
17
 
Penflufen
 
Fungicide C 
yes
 
2-yr combined chronic/CARC in 
rats;  80-week CARC study in 
mice; plus mechanistic non-
standard study DNA synthesis and 
enzyme activity in cultured rat 
hepatocytes then in human 
hepatocytes
 
yes
 
2 AMES studies, CA in V79 
cells, HPRT in V79 cells
 
yes
 
MN study in BM cells
 
01/02/2014 
18
 
Penthiopyrad
 
Fungicide C 
yes
 
52-week chronic in rats; 2-yr CARC study in rats; 7-week in mice; 2-week hepatic enzyme induction in rats and one in mice; 2-weeksin 
rats thyroid function
 
yes
 
19
 
Pseudomonas 
sp. Strain DSMZ 
13134
 
  C 
no
 
Waived as: it is a microorganism 
only tier I test performed
 
no
  
no
  
01/02/2014 
20
 
Pyridalyl
 
Insecticide C 
no DAR available
 
01/07/2014 
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7
 
Pyriofenone
 
Fungicide C yes 
90-day in rats (range finding); 13-
weeks mice range finding); 1-yr 
chronic rat, 2-yr CARC study in rats, 
18-month CARC study in mice
 
yes
 
3 studies: Ames, CA in CHL 
cells; MLA
 
yes
 
3 studies: MN in BM mouse, UDS 
rat hepatocytes and COMET 
mouse liver
 
01/02/2014 
22
 
Pyroxsulam
 
Herbicide C yes 
 2-yr combined chronic/CARC in rats; 
18-month CARC study in mice
 
yes
 
Ames, CA in rat lymphocytes, 
HPRT in CHO
 
yes
 
2 studies  MN in mouse BM and 
UDS in mouse liver
 
01/05/2014 
23
 
S-Abscisic acid
 
Plant growth 
regulator C no 
waived as no effect from short and 
chronic toxicity, low order of toxicity it 
does not increase with exposure) 
natural regulator no genotoxicity 
effect no effect on pregnancy no 
histopathology in tissues and organs 
in 90-days rat study
 
yes
 
Ames, CA in CHO and MLA tk
 
yes
 
 MN in BM cells mice
 
01/07/2014 
24
 
Sedaxane
 
Fungicide C yes 
2-yr combined chronic/CARC in rats; 
80-week CARC study in mice
 
yes
 
Ames, CA, MLA
 
yes
 
MN mouse BM and UDS rat liver
 
01/02/2014 
25
 
Sodium silver 
thiosulphate
 
Plant growth 
regulator C no 
Waived: not performed because 
inexistent exposure and used for 
ornamental flower
 
yes
 
Ames, CA, MLA
 
yes
 
UDS in rat liver
 
01/05/2014 
26
 
Spinetoram
 
Insecticide C yes 
2-yr combined chronic/CARC in rats; 
18-month CARC study in mice
 
yes
 
Ames, CA in rat lymphocytes, 
HGPRT in CHO cells x2 (two 
mixtures)
 
yes
 
MN in vivo in BM cells (x1)
 
01/07/2014 
27
 
Spirotetramat
 
Insecticide C yes 
1-yr study in rats; 2-yr CARC study in 
rats; 18-month study in mice
 
yes
 
Ames, CA, MLA
 
yes
 
2 CA in vivo, 1 UDS
 
01/05/2014 
28
 
Tembotrione
 
Herbicide C yes 
2-yr CARC study in rats (stopped for 
males at 43 weeks); 2-yr study in 
male rats; 18-month study in mice
 
yes
 
Ames, CA, MLA
 
yes
 
MN and UDS
 
01/05/2014 
29
 
Thiencarbazone
 
Herbicide C yes 
2-yr combined chronic/CARC in rats; 
18-month CARC study in mice
 
yes
 
Ames, CA in V79 cells, HPRT 
in V79 cells
 
yes
 
MN in vivo in mice PCEs; no study 
in germ cells because of negative 
results in other genotox tests
 
01/07/2014 
30
 
Valifenalate 
(formerly 
Valiphenal)
 
Fungicide C yes 
2-yr combined chronic/CARC in rats; 
78-weeks CARC study in mice
 
yes
 
Ames, CA, MLA
 
yes
 
MN in vivo mice BM cells; study 
UDS and in germ cells not 
performed because of the results 
of previous studies
 
01/07/2014 
 
 
Legend 
Submission type (A1 to A4): existing active substances divide into four phased evaluations. Stage 1. Substances were reviewed by the Commission and 
the Member States without the participation of EFSA. This stage was completed by the Commission in 2007. Stage 2. For stage 2 EFSA was given the 
responsibility to organise the peer review of the initial risk assessments of the substances. EFSA completed its work in July 2006 publishing ‘conclusions’ 
on 50 substances. Stage 3 and 4. EFSA completed the evaluation of the substances of stage 3 and stage 4 in 2008. C: New active substances. 
CA:  chromosomal aberrations assays 
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MLA:  mouse lymphoma assay mammalian cell gene mutation using Tk gene 
HPRT/HGPRT: mammalian Cell gene mutation using the Hprt and Xprt genes 
MN:  micronucleus test 
UDS: Unscheduled DNA Synthesis 
CHO: Chinese hamster ovary cells 
CHL: Chinese hamster lung cells 
PCEs: polychromatic erythrocytes 
BM: bone marrow  
COMET: DNA damage (COMET assay) 
The information reported was retrieved from EU pesticide Database and available EFSA DAR reports. 
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